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NOS nitric oxide synthase
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Tx transplantation
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VEGF vascular endothelial growth factor
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ZnPP zinc protoporphyrin
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ABSTRACT
Transplant ischemia/reperfusion injury (Tx-IRI) remains among the major clinical challenges 
in organ transplantation. Tx-IRI may result in deleterious short-term consequences such as 
primary graft dysfunction and increased immunogenicity of the allograft, both of which 
enhance the propability for late vascular remodeling and fibroproliferative processes,
ultimately leading to untreatable chronic allograft dysfunction and compromised long-term 
survival. The underlying mechanisms in primary graft dysfunction involve microvascular 
dysfunction culminating in increased vascular permeability, perfusion defects, and leukocyte 
infiltration into the allograft, which may lead to pro-inflammatory and pro-fibroproliferative 
prosesses.
The pleiotropic, cholesterol-independent vasculoprotective effects of statins, 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors, have been well described. Statins improve 
microvascular integrity and perfusion through endothelial cell (EC) and pericyte function. 
Statins attenuate the expression and secretion of angiogenic growth factors and microvascular 
reactivity at the site of vascular injury. Statins seem to have also anti-inflammatory, -
oxidative, and -thrombotic effects. They are widely used for primary and secondary 
prevention of cardiovascular disease. In the transplant recipients, statin treatment decreases 
allograft inflammation and vasculopathy and cardiovascular morbidity. However, the 
therapeutic potential of donor statin treatment against Tx-IRI and microvascular dysfunction 
remains undelineated.
The majority of potential cardiac allograft donors from brain-dead donors do not have 
previous medical track record of cardiovascular diseases nor statin medication. The heart is 
especially susceptible to donor brain death that elicits cardiotoxic pro-inflammatory cytokine 
release, cardiovascular disintegration and poor organ perfusion, which often lead to 
disqualification of a transplant. On the other hand, shortage of donors and different donor-
related factors limit the availability of transplants, and thus lead to the use of organ donors
with extended criteria such as older age. Aggressive donor management could not only 
improve the quality of donated organs, but also expand the donor pool by increasing 
suitability of donors with extended criteria and thus reduce costs of transplantation affecting 
e.g. need for inotropic support and stay at intensive care unit. Based on these clinically 
relevant issues, we chose pharmacological approaches to treat donors to improve allograft 
resistance to Tx-IRI and primary and and chronic allograft dysfunction. 
Donor rats without brain death were treated with a single peroral dose of lipophilic 
simvastatin two hours before heart and kidney removal, which is the clinical time-window to 
treat a brain-dead organ donor. The cardiac allografts were subjected to 4-h and kidney 
allografts to 16-h cold-ischemic preservation to mimic clinical situation and transplanted to 
fully major histocompatibility complex (MHC)-mismatched WF rat recipients. As our current 
clinical practice includes donor treatment with high dose of methylprednisolone, that 
modulates inflammatory state after brain death, we also investigated whether combined donor 
simvastatin and methylprednisolone treatment could be superior to either treatment alone on 
Tx-IRI and allograft survival. 
Here, we report that the expression of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase, a target molecule of statins, was abundant in endothelial cells (ECs) and pericytes 
of normal hearts as well as in glomerular and peritubular microvascular structures of normal 
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kidneys. Rat cardiac and kidney allograft Tx-IRI resulted in profound microvascular 
dysfunction; leakage, perfusion defects and increased adhesivity. 
Donor, but not recipient treatment with peroral single-dose simvastatin two hours before graft 
procurement inhibited microvascular EC and pericyte RhoA/Rho-associated protein kinase 
activation and inter-EC gap formation, vascular leakage, the no-reflow phenomenon, danger-
associated ligand hyaluronan induction, leukocyte infiltration and myocardial and 
tubulointersitital injury. In the chronic rejection model, donor simvastatin treatment inhibited 
cardiac allograft inflammation, TGF-?1 signaling and myocardial fibrosis, vasculopathy and 
improved long-term allograft survival. Furthermore, donor treatment with a combination of 
simvastatin and methylprednisolone was superior in the prevention of Tx-IRI and 
significantly prolonged acute survival of non-immunosuppressed major MHC-mismatched 
cardiac allograft.
In conclusion, donor treatment may target microvascular dysfunction, immunomodulation 
and the initiation of pro-inflammatory and pro-fibroproliferative pathways in cardiac and 
kidney allografts subjected to prolonged ischemia time using a protocol relevant for clinical 
cadaveric transplantation. Minimizing microvascular injury and the activation of innate 
immunity by combined donor simvastatin and methylprednisolone treatment may offer a
novel therapeutic strategy to expand the donor pool and furthermore improve the function of 
donor organs with extended criteria. We have therefore initiated a randomized clinical trial to 
investigate the effect of combined donor simvastatin and methylprednisolone treatment as an 
adjunct therapy on short- and long-term results of cardiac and kidney allografts.
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INTRODUCTION
Allograft organ transplantation means removing an organ from one body (donor) and 
implanting it to a recipient of the same species for the purpose of replacing the recipient's 
diseased or damaged organ. Allografts can be either from living, brain-dead or cardiac-dead 
donor origin. Transplanted solid organs (listed here from the most frequently transplanted to 
the rarest) are kidneys, liver, heart, lungs, pancreas and intestine. 
Shortage of organs limits clinical heart and kidney transplantation. Sixty to 80 patients per 
million inhabitants per year would benefit from cardiac transplantation (Kottke et al. 1990;
Costanzo et al. 1995), but only a quarter of them are placed on the waiting list and one-tenth
will receive a cardiac transplant (Rosengard et al. 2002). Up to two thirds of cadaver donor 
hearts are being discarded (Zaroff et al. 2002; Johnson et al. 2010). Also, the wait-listed 
number of kidney transplant candidates continues to increase annually. Despite high rates of
kidneys recovered for transplant, increasing incidences of those organs are eventually been
discarded due to failure to meet transplant criteria (Matas et al. 2012). Optimistic estimations 
highlight that up to 92% of organs that fail to meet cardiac transplantation criteria on initial 
evaluation could be functionally resuscitated with aggressive pharmacological donor 
management (Wheeldon et al. 1995; Rosendale et al. 2003a). Improving the quality of donor 
organs is also an important economical issue when considering faster weaning from inotropic 
support and shortened need for critical care bed stay (Marasco et al. 2007).
Donor management is indeed a critical step for organ transplantation. In spite of preservation 
techniques exploited at procurement and for transportation, brain-death predisposes cardiac 
and kidney allografts to ischemia-reperfusion -induced rapid alloantigen-independent 
injuries. These innate immune injuries involve a cytokine storm and hemodynamic instability 
during brain death, metabolic changes at loss of oxygen and nutrient supply and finally 
reoxygenation that increases the myocardial injury induced by ischemia alone (Hearse 1977).
By the danger model -theory, the alarm signals or damage-associated molecular patterns
released by damaged cells are the fundamental process for the activation of antigen-
presenting cell (APC) that ultimately controls the balance between host-versus-graft disease 
and tolerance (Matzinger 1994; Anderson et al. 2001; Matzinger 2002). Prolonging cold-
ischemic preservation augments vascular injury independently from allograft 
immunogenicity. Overall, ischemia time of the donor allograft is linked to the early 
development of delayed graft function (DGF) in kidney allografts and primary graft 
dysfunction (PGD) in cardiac allografts. Further, ischemia time induces the progression of 
chronic allograft dysfunction and decreases late survival of the allografts in a linear fashion.
Pharmacological strategies of the immunosuppressive drugs have been primarily designed to
target T and B cell -mediated adaptive immune responses (Bierer et al. 1993; Chen et al. 
1993; Fulton and Markham 1996; Berard et al. 1999). The major problems concerning long-
term immunosuppressive drugs are their many metabolic, cardiovascular, infectious, and 
malignant side effects. Moreover, T and B cell-targeted anti-inflammatory therapies generally 
fail to inhibit the development of allograft fibrosis and vasculopathy. Thus, donor targeted 
drug therapies aiming to prevent danger-associated molecule expression and microvascular 
dysfunction hold promise as a new approach for the prevention of carciac and kidney 
allograft rejection. Moreover, donor treatment exclusively targeting the transplant eliminates
systemic side effects and has no risks of low drug compliance. Statins, HMG-CoA reductase 
inhibitors, have cholesterol-independent microvasculoprotective effects through cytoskeletal 
rearrangement of endothelial cells and their surrounding pericytes.
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In this study, we used simvastatin to approach donor management in experimental heart and 
kidney transplantations. Donor simvastatin treatment could offer novel clinically feasible 
immunomodulatory and microvasculature-targeted adjunct therapy for counteraction of IRI
without inflicting harmful side effects induced by conventional immunosuppressive 
medication. 
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Table 1. Transplantation terminology  
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REVIEW OF THE LITERATURE
1. Clinical heart and kidney transplantation
Introduction
Already in the 16th century, Italian surgeon Gasparo Tagliacozzi performed successful skin 
autografts (a graft taken from the same individual) but consistently failed with allografts (a
graft taken from an individual of the same species, but of different genotype), and finally 
came to the conclusion about the "force and power of individuality" in his work De curtorum 
chirurgia per insitionem (1597).
Figure 1. De curtorum chirurgia per insitionem, 1597
Alexis Carrel, after his skillful operations with arteries or veins, performed the first 
successful experimental kidney transplantations in the early 20th century and laid the basis for 
later transplant surgery (Carrel and Guthrie 1905, 1906). Improving donor preservation, 
surgical techniques and introduction of immunosuppression were needed to achieve 
acceptable long-term survival (Shumacker 1994).
The first successful transplant in man was performed by Joseph Murray in Boston at Peter 
Bent Brigham Hospital (currently Brigman and Women’s Hospital) in 1954 (Guild et al. 
1955). This renal transplantation took five and half hours and was performed between 
genetically identical twins to eliminate any problems of immune reaction. Cortisone 
medication that was used to prevent and treat acute rejections enabled organ transplantations 
from cadaveric sources. Kidney was the most approachable organ for transplantion because it 
was relatively easy to remove and implant, tissue typing was easily manageable and in the 
case of allograft failure, dialysis was available. Success with the kidney led to attempts with 
other organs. 
The exhaustive development of the heart-lung machine, solving perfusion issues and 
developing surgical techniques by Shumway and Lower at Stanford University enabled 
successful heart transplantations, first performed by Christiaan Barnand and his team of thirty 
people in an operation that lasted for nine hours at Groote Schuur Hospital in Cape Town in 
1967.
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Understanding transplant immunology and the underlying mechanisms of acute and chronic 
rejection led to groundbreaking discoveries in this area (Billingham et al. 1951; Calne 1963).
The identification of an immunosuppressant drug called cyclosporine, derived from soil 
fungus (approved by FDA 1983), was a major breakthrough for the development of organ
transplantation as a standard clinical procedure for the treatment of end-stage diseases (Borel 
et al. 1976).
Indications and candidate characteristics
Worldwide, the estimated amount of people suffering from end-stage chronic kidney disease
(CKD) is 1.7 million, and the number is still increasing since the rising prevalence of type 2 
diabetes mellitus and diabetic nephropathy (Bendorf et al. 2013). Similarily, end-stage heart 
failure (HF) has reached epidemic proportions affecting up to 5.8 million people in USA and 
over 23 million worldwide (Liu and Eisen 2013). Thus, waiting lists for kidney 
transplantation have nearly doubled between 1999 and 2008, with more people dying each 
day as a transplant candidate (Axelrod et al. 2010). 
Based on data from 109 countries, around 78,000 renal and 5,900 cardiac transplantations 
were performed worldwide in 2012 (The Global Observatory on Donation and 
Transplantation, produced by the WHO-ONT collaboration), of which ca 4100 cardiac 
transplantations were reported to the registry of the International Society for Heart and Lung 
Transplantation (ISHLT) (Lund et al. 2013). Worldwide, majority of renal transplants were
from deceased donor origin (The Global Observatory on Donation and Transplantation, 
produced by the WHO-ONT collaboration) (Axelrod et al. 2010).
Primary indications for kidney transplantations were diabetes, glomerulonephritis, 
hypertension, polycystic kidney disease, structural reasons, pyelonephritis and renovascular 
disease (Matas et al. 2013). For heart transplantations, leading indications were ischemic and 
non-ischemic cardiomyopathy, coronary artery disease, congenital and valvular heart disease 
or retransplantation (Colvin-Adams et al. 2013) (Table 2).
Table 2. Transplant recipient characteristics (primary cause of disease), modified from the OPTN/SRTR 2011
Annual Data Report.
Kidney transplant recipients Heart transplant recipients
Pediatric Pediatric
Structural 30.5 Congenital defect 43.4
Focal segmental glomerulosclerosis (FSGS) 12.6 Dilated myopathy (idiopatic/myocarditis) 33.8 (29.3/4.5)
Glomerulonephritis 11.4 Restrictive myopathy 4.3
Other 45.5 Other 18.5
Adult Adult
Diabetes 25.7 Cardiomyopathy 54.4
Hypertension 23.5 Coronary artery disease 37.9
Glomerulonephritis 19.2 Congenital disease 3.6
Cystic kidney disease 12.8 Valvular disease 1.4
Other 18.8 Other 2.7
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Brain death
The brain is covered by a rigid skull. Vasogenic or cytotoxic edema may increase intracranial 
pressure (ICP) over mean arterial pressure (MAP) resulting in non-existent cerebral perfusion 
pressure (CPP) and leading to irreversible loss of all brain and brainstem activity defined as
brain death (The honorary secretary of the Conference of Medical Royal Colleges and their 
Faculties 1976; The Quality Standards Subcommittee of the American Academy of 
Neurology 1995; Wijdicks et al. 2010; Nakagawa et al. 2011). Thus, neurocritical care 
patients are typically treated with osmotic diuretics and vasopressor support (Rosner et al. 
1995; Qureshi et al. 1999; Kroppenstedt et al. 2003; Kerwin et al. 2009; Sookplung et al. 
2011). Mild hypothermia might be included not only to reduce metabolic activity and oxygen 
demand, but also to increase CPP due to lowered brain edema and ICP in subacute phase,
improving survival and neurological recovery (Gal et al. 2002; Polderman et al. 2002).
Cerebral protective strategy may, however, burden peripheral organs via electrolytic 
disbalance, impaired perfusion and arrythmia susceptibility (Arbour 2005; Mascia et al. 2009;
Dictus et al. 2009; Bohman and Schuster 2013) (Table 3). Events preceding brain death, like 
traumatic brain injury and subarachnoid (SAH) or intracerebral haemorrhage (ICH) aggravate 
a systematic inflammatory response (Yoshimoto et al. 2001; Dhar and Diringer 2008).
Animal and human studies reveal that brain death elicits tremendous changes in stress 
hormone levels, sympathic nervous activity, systemic blood pressure and secretion of 
proinflammatory cytokines and procoagulant factors. Further, the combination of primary 
cause and consequent brain death results in impaired haemodynamics, metabolic switch to 
anaerobic state, increased apoptosis and endothelial activation of peripheral organs (Chen et 
al. 1996; Herijgers et al. 1996; van der Hoeven et al. 1999; Chiari et al. 2000; Birks et al. 
2000a; Stangl et al. 2001; Szabo et al. 2002; Nijboer et al. 2004; Lisman et al. 2011). All of 
these events can be linked with post-transplant allograft dysfunction and alloreactivity (Birks 
et al. 2000b; Lopau et al. 2000; Murugan et al. 2008).
Table 3. Adverse effects of cerebral protective stategy on neurocritical care patient peripheral organ function
Cerebral protective strategy of neurocritical care patients Adverse effects on cadaver donor peripheral organ function 
Osmotic diuresis for reducing cerebral edema Hyperosmolarity, hypovolemia
Vasopressor support for maintaining cerebral perfusion pressure 60-70mmHg Vascular resistance, impaired organ perfusion, lactic acidosis
Mild hypothermia (33-34°C) for protection against focal cerebral ischemia Arrhythmia, reduced myocardial contractility due to decreased Ca2+ sensitivity
Donor management 
The steadily declining number of brain dead organ donors due to the improvement in
prevention and treatment of traumatic brain injury and intracranial bleeding (SAH and ICH) 
(Kompanje et al. 2006) with the concurrently increasing number of heart and kidney recipient 
candidates has drawn the focus on the efforts to identify potential donors (Gortmaker et al. 
1996; Sheehy et al. 2003). In addition, there is rising interest in the use of donors with 
extended criteria or use of cardiac death/non-heartbeating donors for the expansion of the 
donor pool (Tuttle-Newhall et al. 2009). The heart is escpecially susceptible to donor induced 
injuries as demonstrated by low utilization proportion and fairly poor long-term survival
(Smits et al. 2012; Samsky et al. 2013). Based on these aspects, management of suboptimal
organ donors has received increasing attention in the field of transplant research (Smith 2004;
Wood et al. 2004; Arbour 2005).
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A pioneering experimental study screening potential donor treatment has laid basis on the 
clinical use of high-dose methylprednisolone (MP) (Soots and Hayry 1978). Complementary 
animal studies have confirmed the advantage of donor MP treatment in order to enhance
myocardial viability and contractile recovery resulting in faster weaning from inotropes
(Toledo-Pereyra and Jara 1979; Segel et al. 1997; Lyons et al. 2005). The guidelines for 
aggressive donor managent recommend the use of hormonal resuscitation/replacment (3HR) 
involving vasopressin infusion and triiodothyronine or l-thyroxine (Novitzky et al. 1988;
Novitzky et al. 1990; Jeevanandam et al. 1994; Jeevanandam 1997; Salim et al. 2001; Salim 
et al. 2007) in combination with MP bolus to induce graft utilization and quality (Rosengard 
et al. 2002; Zaroff et al. 2002; Rosendale et al. 2003a, 2003b). However, some studies have 
challanged the benefit of 3HR therapy (Randell and Hockerstedt 1992; Goarin et al. 1996;
Perez-Blanco et al. 2005; Venkateswaran et al. 2009b; Venkateswaran et al. 2009a;
Macdonald et al. 2012).
Organ preservation
Successful organ preservation is based on optimal temperature, the use of modern 
cardioplegia and preservation solutions and acceptable ischemia time. Additionally, 
controlled restoration of blood flow is crucial as, paradoxically, reperfusion generates an 
injury that greatly exceeds the injury induced by ischemia alone (Hearse 1977; Billingham et 
al. 1980). There is renewed interest in mechanical perfusion, supporting metabolic activity by 
delivering oxygen and nutrients to the graft and providing microvascular wall shear.  
 
Cold cardioplegia, to ensue repolarization (electromechanical silence; asystole) and minimal 
metabolic demand, is usually based on high potassium concentrations of cold crystalloid 
solutions. Euro-Collins preservation solution prolonged safe cold preservation time of kidney 
transplants to 36-48 hours, making tissue matching, long-distance retrieval and reduction of 
emergency surgery possible (Jamart and Lambotte 1983). The University of Wisconsin (UW) 
solution, mimicking intracellular-like consistensy, was the first transplant-designed 
preservation solution. UW solution contains high energy phosphate precursors, H+ buffering 
capacity, antioxidant properties, and hydroxyethyl starch (HES) containing colloids to 
prevent hypothermically induced cell and intracellular space swelling (edema). The UW
solution soon displaced the Euro-Collins solution, due to superior cold storage properties
both in kidney and heart transplants (Ploeg 1990; Ploeg et al. 1992; Stringham et al. 1998;
George et al. 2011). Despite improvements in preservation solutions, escpecially the heart is 
vulnerable to hypothermic static cold preservation, cold ischemia time being the main risk 
factor for poor outcome (Tanaka et al. 2005). Generally, static cold storage of heart 
transplants should not exceed 4 hours (Marasco et al. 2005), whereas novel preservation 
techniques where the heart is continuously perfused with a normothermic blood may start a
new era in cardiac preservation. Current median organ preservation times are 2-3 hours for 
cardiac and 12-21 hours for kidney transplants (OPTN/SRTR 2011 Annual Data Report: 
Heart and kidney). Mechanical continuos perfusion of donor hearts appears a promising 
turning point to answer perpetual donor shortage and the ever-increasing demand of use of 
donors with extended criteria, allowing tissue matching and organ sharing in heart transplants
(Rosenbaum et al. 2008; Yang et al. 2013). Similarly, pulsatile machine perfusion of kidneys 
is associated with improved early and long-term renal function compared to kidneys 
subjected to static cold storage (Polyak et al. 2000; Bathini et al. 2013).
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Primary graft dysfunction and delayed graft function
Primary graft dysfunction (PGD) is a devastating complication of the immediate post-
operative period after heart transplantation. PGD is usually manifested by severe right or 
biventricular failure, leading on early institution of mechanical circulatory support (Marasco 
et al. 2005). PGD accounts nearly up to a quarter of heart transplants, and is the leading cause 
of early heart mortality after transplantation, exceeding even 50% in cases of PGD (Cosio 
Carmena et al. 2013). However, the 1-month mortality due to PGD differs 10-fold in previous 
studies, so does the practice in circulatory support between the centers/units [extracorporeal 
membrane oxygenation (ECMO), intra-aortic balloon pump (IABP), total artificial heart 
(TAH) or ventricular assist device (VAD)] (Cosio Carmena et al. 2013). The high amount of 
donor inotrope support, graft ischemia time exceeding 4 hours and high donor age are the 
major risk factors for PGD (Marasco et al. 2005; Santise et al. 2009; D'Ancona et al. 2010).
In particular, in heart transplants from the donors with extended criteria, PGD complicates
immediate post-operative recovery and discharge from the hospital (Iyer et al. 2011).
Delayed graft function (DGF) is a multifactorial acute renal failure after kidney 
transplantation. DGF occurs more frequently among deceased donors affecting still 60% of
kidney transplants (Szwarc et al. 2005; Bronzatto et al. 2009). DGF features clinically 
oliguria and histologically reversible acute tubular necrosis (ATN). Prolonged cold ischemia 
time is associated with higher incidence of DGF (McLaren et al. 1999; Kayler et al. 2011;
van der Vliet and Warle 2013). Even though DGF is reversible, it may predispose the graft to
an increased risk for acute rejection episode and reduced graft function and affect the long-
term survival (Ojo et al. 1997; Yarlagadda et al. 2009; Eid et al. 2013; Raimundo et al. 2013).
PGD and DGF may multiply the total costs of transplantations due to increases in intropic 
and mechanical circulatory support after heart transplantation and need for renal replacement 
therapy after of kidney transplantation leading to prolonged hospitalization of the recpients 
(Marasco et al. 2007; Schnitzler et al. 2011; Gheorghian et al. 2012). Thus, treatments to
minimize detrimental effects of prolonged cold ischemia time impoving early post-operative 
graft function are also a major economical issue.
Allorecognition and antigen presentation 
During brain death, organ procurement and preservation, and restoration of blood flow, an 
allograft faces multiple non-immunological injuries that potentiate allograft immunogenecity. 
Released by the allograft injury, damage-associated molecular patterns (DAMPs) - ligands 
for Toll-like receptors (TLRs) - are believed to be crucial in triggering innate and subsequent 
adaptive immune responses (Mbithi et al. 1991; Matzinger 1994; Medzhitov et al. 1997)
(Figure 2).
In the allogenic transplantation setting, according to the self-nonself and danger models,
cellular damage during organ transplantation together with direct/indirect antigen 
presentation are required for the activation of cellular and humoral effector mechanisms 
aiming to destruct a foreign body (Janeway 1992; Medzhitov and Janeway 1997). In direct 
antigen presentation, CD4+ or CD8+ T cells of the recipient recognize allogenic major
histocompatibility complex (MHC class I and II) molecules (non-self antigens of the graft) by
donor “passenger” antigen-presenting cells (APC; mainly dendritic cells). Furthermore, the 
presence of donor “passenger” T cells may lead to direct activation of recipient autoreactive 
B cells (Win et al. 2009). Indirect antigen presentation requires the activation of the recipient 
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APC by recognition of endogenous molecules released by tissue injury (DAMPs), expression 
of donor antigens on the recipient MHC molecules and co-stimulatory activity by the same 
cells, and antigen presentation to unprimed T cells in secondary lymphoid organs such as 
lymph nodes and spleen (Liu and Janeway 1992; Fangmann et al. 1992; Lenschow et al. 
1996; Vella et al. 1997; Benichou et al. 1999; Pietra et al. 2000; Whitelegg and Barber 2004).
Antigen presentation leads to the activation, clonal expansion and migration of primed 
alloreactive T cells to the allograft (classical pathway of cellular immune response). Th2 
helper T cells further trigger B cells to participate in allograft rejection by secreting 
antibodies directed to donor antigens (humoral immune response) (Terasaki 2003;
Montgomery et al. 2004; Dragun 2008). Interestingly, indirect antigen presentation was 
reported to occur also independently of the secondary lymphoid organs, in the transplanted 
allogenic organ (tertiary lymphoid organ) (Zhou et al. 2003; Nasr et al. 2007). On the other 
hand, the involvement of anti-inflammatory regulatory T cells, alternatively activated (M2)
macrophages and certain subpopulatations of dendritic cells may counterbalance immune 
activation and promote tolerance for the graft (Banchereau and Steinman 1998; Nishimura et 
al. 2004; Tiemessen et al. 2007; Swirski et al. 2009; Wood et al. 2011; Manicassamy and 
Pulendran 2011).  
Figure 2. Simplified presentation of how donor brain death and transplant ischemia/reperfusion injury result in 
adaptive immune activation.
Acute and chronic allograft rejection
Classifications of renal and cardiac allograft rejections are based on histological analysis of 
allograft biopsy (Billingham et al. 1990; Solez et al. 1993). Current immunosuppressive 
medication has markedly reduced the rate of acute rejections both in kidney and heart 
allografts, prolonged ischemia time and MHC-mismatch being the major risk factors for 
acute rejection. Acute rejections may occur between the first week and several months after 
the transplantation. Acute rejections are caused either by T cell dependent acute cellular 
rejection or B cell dependent acute antibody-mediated rejection and may decline allograft 
survival (Joseph et al. 2001). Despite impressive improvement in short-term graft survival, 
the management of chronic rejection has improved only little (Pascual et al. 2002; Meier-
Kriesche et al. 2004). As compared to acute rejection, chronic rejection comprises of different 
immunological nature (Hayry 1996). Chronic rejection is a response to ongoing, low-grade 
injuries to the allograft EC (Hayry 1996). Chronic inflammatory and fibroproliferative 
processes are common manifestanions of chronic rejection in all transplanted organs. 
Chronically rejecting renal allografts develop arterial intimal thickening, glomerular sclerosis 
and tubular atrophy, while cardiac allografts show diffuse cardiac allograft vasculopathy and 
fibrosis. Chronic allograft dysfunction as a consequence of chronic rejection is the main 
reason for the poor long-term survival of heart and kidney allografts. Adaptive and humoral 
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immune responses may link ischemia-reperfusion injury to the progression of chronic 
rejection and reduced long-term survival (Syrjala et al. 2010; Fuquay et al. 2013).
Immunosuppressive medication
The introduction of glucocorticoids to prevent acute rejections by suppressing immune 
responses laid the basis on the success in allogenic transplantation (Starzl et al. 1964; Hume 
et al. 1964; Barnard 1969). Co-morbities of chronic steroid use became widely recognized
including high susceptibility to infections, metabolic (weight gain, glucose intolerance), 
cardiovascular (hypertension, hyperlipidemia) and skeletal (osteopenia, impaired growth) 
disorders among others (Siegel et al. 1972; Park et al. 1984; Citterio 2001). The introduction 
of calcineurin inhibitor (CNI) cyclosporin A (CsA) revolutionized organ transplantation by
the dramatic improvement in the outcome of transplant recipients (Kolata 1983). CNI 
exposure may result in acute and chronic nephrotoxicity (Calne et al. 1978; Nankivell et al. 
2003; Naesens et al. 2009). Chronic nephrotoxicity being, however, overstated against the 
risk of rejections in CNI dose reduction/avoidance at the present immunosuppressive regimen 
repertoire (Gaston 2009; Issa et al. 2013). Indisputably, introduction of these second 
generation immunosuppressive drugs that more selectively target T and B cell responses, has
enabled steroid minimization/weaning in maintenance and acute rejection 
immunosuppression by a marked reduction of steroid-related unwanted side effects both in 
kidney and heart transplant recipients (Ahsan et al. 1999; Vincenti et al. 2003; ter Meulen et 
al. 2004; Rostaing et al. 2005; Pelletier et al. 2006; Teuteberg et al. 2008).
New immunosuppressive drugs have enabled a more complex choice of immunosuppressive
regimen combinations. The distinctive immunosuppressive drug use between kidney and 
cardiac transplant recipients reflects the different efficacy, and systemic and organ specific 
toxicity profiles of current immunosuppressive regimens (Pirsch et al. 1997; Jain et al. 2000;
Heisel et al. 2004 ; Chapman 2011; Almeida et al. 2013). Over the last years, anti-interleukin-
2 receptor or thymoglobulin induction therapy with tacrolimus and mycophenolate mofetil 
based maintenance therapy has become the most commonly used combination for solid-organ 
transplant recipients both in kidney and heart transplant recipients (Table 4).
Table 4. Prevalence and the mechanisms of action of immunosuppressive drugs prescribed to kidney and 
cardiac transplant recipients at the time of transplantation (and 1-year post-Tx), modified from the OPTN/SRTR 
2011 Annual Data Report. 
Immunosuppression Pediatric Adult Pediatric Adult
Maintenance therapy Tacrolimus 94.0 89.7 83.2 85.3
Cyclosporine 1.6 3.9 15.2 9.5
Mycophenolate Mofetil/Sodium 92.6 91.2 90.0 91.9
Azathioprine 1.2 0.4 6.2 1.2
Corticosteroids 63.8 (62.5) 66.2 (65.0) 68.8 (36.1) 89.2 (57.2)
Sirolimus (and Everolimus) 0.3 (5.9) 3.2 (5.9) 1.6 (7.2) 0.6 (6.9)
Induction therapy Anti-thymocyte globulin 48.9 62.3 48.0 19.7
Basiliximab/Daclizumab 35.0 24.6 25.7 26.5
Group Mechanism of action Immunosuppressive target
Calcineurin inhibitor (Tacrolimus, Cyclosporine) prevents  interleukin-2 transcription through nuclear factor T-cell activation
Anti-metabolite (Mycophenolate Mofetil/Sodium, Azathioprine) prevents DNA synthesis through de novo  purine synthesis T- and B-cell proliferation 
Corticosteroid (Methylprednisolone etc.) prevents protein synthesis of pro-inflammatory cytokines, hyaluronic acid inflammatory responses
mTOR inhibitor (Sirolimus/Everolimus) prevents interleukin-2 responses through mTOR complex 1 T- and B-cell activation
Anti-thymocyte globulin (Thymoglobulin/ATGAM) monoclonal rabbit/horse T-cell antibody circulating T-cell number
IL2-R mAb (Basiliximab/Daclizumab) prevents interleukin-2 receptor activity through the alpha-chain (CD25) T-cell activation
Kidney transplant recipients Cardiac transplant recipients
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Outcomes
The 1-year survival rates of heart and kidney transplants have substantially impoved due to
advancements in immunosuppressive medication, monitoring and management of acute 
rejections, and patient care (Johnson et al. 2010; Axelrod et al. 2010). Currently, the 1-year
survival rate for cardiac allografts was 91% and that of kidney allografts 96.8% and 91.6% of 
living and deceased donors, respectively (OPTN/SRTR 2011 Annual Data Report: Heart and
kidney). Despite, for the past 20 years survival beyond the first year after transplantation has 
remained relatively constant (Lodhi et al. 2011; Stehlik et al. 2012). Cardiac allograft 
vasculopathy and side-effects of immunosuppressive medication such as cardiovascular 
diseases, infections, and malignancies are the main causes of allograft loss and death 1 year 
after transplantation. (Colvin-Adams et al. 2013; Matas et al. 2013). At 5 years, cardiac 
allograft vasculopathy and late graft dysfunction account for 32%, malignancies for 23%, and 
infections for 10% of deaths of heart transplant recipients. Similarly of kidney transplant 
recipients with a specified cause of death, 21% died due to malignancies, 21% as a
consequence of cardiac disease, and 16% for infections. Adjusted 5-year patient survival rates
were 75% for heart transplant recipients and 85% and 74%, respectively, for kidney 
transplant recipients of living and cadaveric donor kidney (OPTN/SRTR 2011 Annual Data 
Report: Heart and kidney)(Colvin-Adams et al. 2013; Matas et al. 2013). Half-lives were 12.5
years for cardiac transplant recipients, and 13.8 and 9.7 years for kidney transplant recipients 
of living and cadaveric donor kidney, respectively (OPTN/SRTR 2011 Annual Data Report: 
Heart and kidney). Table 5 summarizes the adjusted 3-month, 1-, 3-, 5- and 10-year graft 
survival rates of heart and kidney transplants.  
Table 5. Adjusted graft survival of heart and kidney transplants (%), modified from the OPTN/SRTR 2011 
Annual Data Report. Tx, transplantation. 
Time (Tx year) Heart transplantation Kidney transplantation
living / deceased donor
3-month (2010) 94.4 98.6 / 96.2 
1-year (2010) 91.4 97.0 / 92.9
3-year (2008) 81.8 91.8 / 84.4
5-year (2006) 74.8 84.7 / 73.7
10-year (2001) 56.5 61.1 / 46.9
Microvascular injury in allograft ischemia-reperfusion and chronic rejection 
Normally, the adult microvascular network is in quiescent state. Microvascular endothelial 
cells (ECs) form barrier integrity avoiding leukocyte adhesion and thrombogenicity, and the 
surrounding pericytes are relaxed maintaining uninterrupted blood flow. In addition, 
endothelial cells interplay with cardiomyocytes regulating cardiomyocyte contractile function
and survival (Narmoneva et al. 2004; Xaymardan et al. 2004; Hsieh et al. 2006b; Hsieh et al. 
2006a). In organ transplantation, Tx-IRI induces microvascular dysfunction via a pro-
inflammatory cytokine storm, vascular permeability and perfusion disturbances, leukocyte 
adhesivity and thrombosis, and vasoconstriction. Microvascular dysfunction also predisposes 
the allograft to intimal smooth muscle cell proliferation (Hayry 1996; Lemstrom et al. 2002).
Ultimately, endothelial cell dysfunction in transplants predicts the formation of chronic 
allograft vasculopathy and impaired long-term outcome (Hollenberg et al. 2001; Marti et al. 
2001; Tona et al. 2006; Kubrich et al. 2008). Proinflammatory endothelium from old donors 
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seems to be especially vulnerable to Tx-IRI exposing allografts to increased immunogenicity 
and early and late adverse events (de Fijter et al. 2001; Korkmaz et al. 2013). Lymphatic 
endothelial cells are also crucial in immune surveillance as their activation regulates 
leukocyte traffick and rejection in allografts (Nykanen et al. 2010). Overall, 
vasculoprotection targeted therapy in Tx-IRI may represent an important strategy against 
adaptive immune response in the development of acute and chronic allograft dysfunction 
(Basile 2007).
Vascular wall shear stress
The vascular wall is continuously subjected to dynamic mechanical forces of blood flow in 
the form of pulsatile vertical pressure and laminar shear stress and oscillatory shear forces 
created by the heart beat. Shear stress and cyclic stretch play an important role in endothelial 
functions by inducing secretion of shear stress dependent vascular stabilizing, anti-
inflammatory, anti-apoptotic, anti-thrombotic transcription factor KLF-2 and 
vasculoprotective down-stream genes eNOS and HO-1 (SenBanerjee et al. 2004; Lin et al. 
2005; Huddleson et al. 2005; Fledderus et al. 2007; Ali et al. 2009; Boon et al. 2010; van 
Agtmaal et al. 2012). Endothelial shear stress also inhibits the expression of pro-
inflammatory and vascular destabilizing transcription factors NF-kB and Rho GTPases (Chiu 
et al. 2005; Tzima 2006; Wang et al. 2007), and leukocyte recruitment and vascular smooth 
muscle cell (vSMC) proliferation (Ando et al. 1994; Sheikh et al. 2003; Wang et al. 2006;
Matharu et al. 2008).
Lack of vascular wall haemodynamic forces, as during static cold preservation of organ 
transplants, predisposes allografts to cytoskeletal rearrangement and barrier disruption
(Morita et al. 1993; Cheng et al. 2007). Strategies to improve vascular homeostasis during 
preservation and organ transportation involve mechanical perfusion (discussed above in 
“Organ Preservation” on pages 16-17) or pharmacological interventions stabilizing vascular 
homeostasis (EC viability) by affecting the expression and activity of blood flow-regulated 
genes (discussed later in “HMG-CoA reductase inhibitors” on pages 26-29).    
Leakage and perfusion defects (the no-reflow phenomenon)
In quiescent vascular wall, endothelium forms an integral barrier against vascular leakage and 
leukocyte extravasation and pericytes and vSMCs are in relaxed state responding for vascular 
patency. During allograft procurement and acute hypoxia, activation (phosphorylation) of
Rho GTPases, myosin light chain (MLC)2 and ezrin-radixin-moesin (ERM) proteins re-
organize actin-myosin II cytoskeleton of vascular endothelial cells and perivascular pericytes 
and SMCs (Chrzanowska-Wodnicka and Burridge 1996; Amano et al. 1996; Hall 1998;
Wojciak-Stothard et al. 2005). Hypoxia-induced rapid actin stress-fiber formation
mechanistically causes endothelial adherense and tight junction opening and sustained 
pericyte/vSMC contraction (Kutcher and Herman 2009; Yemisci et al. 2009). Hypoxic stress-
fiber formation as well as hyperoxic oxidative stress in re-oxygenation further trigger 
vascular destabilizing angiopoietin (Ang)-2 and constrictive endothelin (ET)-1 release from 
EC Weibel-Palade bodies and impair endothelial NO (eNOS) expression and its 
autovasodilatory responses (Shyu et al. 2003; Bhandari et al. 2006; de Vries et al. 2013).
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Together, these result in vascular permeability and deteriorate tissue perfusion (the no-reflow 
phenomenon). RhoA-Rho kinase pathway activity has turned out to be a notable therapeutic 
target in the prevention of microvascular injury during IRI (Prakash et al. 2008; Li et al. 
2011; Kentrup et al. 2011; Shi and Wei 2013).
Endothelial cell interactions 
Communication between endothelium and cardiomyocytes regulates cardiomyocyte 
proliferation, organization, maturation, and function (Brutsaert 2003). Under in vitro
coculture conditions cardiomyocytes exclusively survive in EC closeness (resembling the in 
vivo situation where cardiomyocytes are in close spatial relationship with endothelial cells of 
the capillary network) (Narmoneva et al. 2004; Davis et al. 2005) (Figure 3). Furthermore, 
endothelial cells may induce myocyte hypertrophy as a response to persistent hemodynamic 
stress (pressure overload; high blood pressure) (Tirziu and Simons 2008). Discovery of 
endothelial pro-survival effect on cardiomyocytes has challanged the idea of capillary 
endothelial cells being simply suppliers of oxygenated and nutritious blood and suggests a
more complex role in cardiac health and viability. 
Endothelial cell derived angiogenic growth factor platelet derived growth factor (PDGF)-BB 
directly preserves cardiomyocyte survival and systolic function via PI3K/Akt -pathway in 
myocardial IRI and infarction models (Hsieh et al. 2006a; Hsieh et al. 2006b). Conversely, 
the fact that PDGF-B-chain inhibition increased arterial SMC apoptosis, points out that 
targeting angiogenic growth factors could be used to induce neointimal regression aiming to 
reverse hyperplasia lesions (Leppanen et al. 2000; Schermuly et al. 2005). This is in 
accordance with the previous findings in experimental chronic rejection models, where 
cardiac allograft vasculopathy was minimized by blocking PDGF and vascular endothelial 
growth factor (VEGF) receptor activity (Lemstrom et al. 2002; Sihvola et al. 2003; Nykanen 
et al. 2005).
A B
Figure 3. (A) Heart is more than just a bunch of cardiomyocytes. Roughly, myocardium consist of an equal 
amount of cardiomyocytes and capillaries; nearly 2000 per mm2 each. Inset, myocyte membranes (red), 
capillaries (green) and DAPI+ nuclei (blue) reprinted from Jaba IM et al., J Clin Invest., 2013 Apr 
1;123(4):1718-31 with the permission from the American Society for Clinical Investigation (left) and Hsieh PC 
et al., Annu Rev Physiol., 2006;68:51-66 with the permission of Annual Reviews (right). (B) Over 95% of the 
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cultured neonatal cardiomyocytes (red) choose to migrate to or survive in proximity with microvascular 
endothelial cells (green) from Narmoneva DA et al., Circulation, 2004 Aug 24;110(8):962-8 with the permission 
from the American Heart Association and Lippincott Williams and Wilkins (LWW).
Endothelial-to-mesenchymal transition (fibroproliferation) 
Interstitial fibrosis, a characteristic feature of chronic rejection in the allografts, accounts for 
accumulation of fibroblasts in the interstitium with phenotypic appearance of myofibroblasts 
and extensive deposition of extracellular matrix. Intersitial fibrosis replaces the functional 
parenchyma and contributes to the progressive loss of its function. Intersititial fibrosis may 
arise from proliferation of resident fibroblast, the migration and differentiation from bone 
marrow -derived cells and vascular pericytes, and the epithelial-to-mesenchymal transition
(EMT) (Iwano et al. 2002; Broekema et al. 2007; Lin et al. 2008). Currently, there is no 
specific treatment to control interstitial fibrosis. 
Mesenchymal transition is critical in the embryonic development of heart and kidney (Hay 
and Zuk 1995; Eisenberg and Markwald 1995). Recently, endothelial-to-mesenchymal 
transition (EndMT) was discovered as a remarkable contributor to interstitial fibrosis of the 
transplant as up to half of fibroblasts co-express the endothelial marker (Zeisberg et al. 2007;
Zeisberg et al. 2008). Similar underlying mechanisms that evoke vascular dysfunction relate
to the fibroproliferation of allografts (Babu et al. 2007). Both pathophysiological
circumstances involve endothelial cytoskeletal rearrangement, loss of inter-endothelial 
integrity and detachment from supporting basal lamina. Hypoxia causes HIF-1? activation, 
which participates in MLC2 phosphorylation and endothelial barrier disruption (Qi et al. 
2011; Wang et al. 2013), but also promotes mesenchymal transition (Higgins et al. 2007).
Moreover, loss of vascular inter-endothelial junction VE-cadherin in ischemia-reperfusion 
injury promotes peripheral blood mononuclear cell infiltration, pro-fibrotic TGF-?1
expression and EndMT (Sutton et al. 2003; Li et al. 2009; Ghosh et al. 2010; Vockel and 
Vestweber 2013).
Vascular remodeling 
Allograft vasculopathy, a manifestation of chronic rejection, is one of the main reasons that 
limit long-term survival of renal and cardiac allografts. It is characterized by structural 
changes - atypical from atherosclerotic plaques - concentric intimal proliferation and vascular 
occlusion, and is detectable in half of cardiac transplants by 5 years after transplantation (Gao 
et al. 1989; St Goar et al. 1992; Rickenbacher et al. 1995). The pathogenesis of allograft 
vasculopathy is not completely understood, but nonimmunological innate vascular injury 
together with chronic alloimmune dependent pro-inflammatory milieu are believed to trigger
SMC activation and fibroproliferative response in the allograft. This includes upregulation of 
chemokines and pro-inflammatory cytokines, mononuclear cell infiltration and the 
recruitment, proliferation and matrix synthesis of vascular SMC in the intima of injured 
arteries, and occlusion of the vascular lumen by neointimal formation (Rahmani et al. 2006;
Schober 2008). Vascular SMC are traditionally believed to derive from the local vessel wall;
however, in some instances and to some extent, at least in animal models recipient-derived 
hematopoietic progenitor cells may also contribute to the neointimal formation (Hillebrands 
et al. 2001; Li et al. 2001; Shimizu et al. 2001; Hu et al. 2002).
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Allograft EC forms the interface/barrier with recipient´s immune system and is the primary 
target of recipient immunologic defences (Pober et al. 1984; Salomon et al. 1991).
Endothelial function in the allografts declines over time (Treasure et al. 1992). Endothelial 
dysfunction is suggested to play a central role in the progression of allograft vasculopathy 
and to predict independently the outcome of the patient (Davis et al. 1996; Schachinger et al. 
2000; Hillebrands et al. 2000; Marti et al. 2001; Hollenberg et al. 2001; Kubrich et al. 2008).
Growth factors play a crucial role in the physiological healing processes, e.g., in endothelial 
repair, angiogenesis and scar formation. According to the response-to injury theory, however, 
persistent vascular endothelial injury of transplanted organs due to chronic alloimmune 
responses results in an uncontrolled repair process by prolonged growth factor expression
leading to a pathological fibroproliferative disease (Lemstrom et al. 1995). Preventing
multifactorial allograft vasculopathy necessitates the development of pharmacological 
compounds capable of prophylaxis of EC dysfunction during transplantation procedure, 
rather than therapy directed to fight neointimal formation by inhibiting SMC proliferation or 
pre-existing lesions by inducing SMC apoptosis (Lemstrom et al. 1995).
HMG-CoA reductase inhibitors
Statins are drugs that inhibit the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase and lower blood cholesterol levels in patients with hyperlipidemia (Figure 4).
Based on the solid evidence in multiple large clinical trials of its effectiveness and safety,
statins are recommended for primary and secondary prevention of cardiovascular diseases for 
a wide range of high-risk patients, regardless of their initial cholesterol levels (the 
Scandinavian Simvastatin Survival Study 1994; Shepherd et al. 1995; (LIPID) Study Group 
1998; the LIPID trial follow-up 2002; Cannon et al. 2004; LaRosa et al. 2005; Amarenco et 
al. 2006).
Figure 4. Simplified diagram of lipid lowering and pleiotropic mechanisms of action of statins. 
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Pleiotropic effects
In addition to lipid lowering ability, statins have a plethora of beneficial pleiotropic effects 
such as improvement of vascular EC and pericyte function, reduction of inflammation, and 
inhibition of tissue remodeling independent of lipid lowering (Endres et al. 1998; Koh 2000;
Wilson et al. 2001; Wilson et al. 2002; Bonetti et al. 2002; Zhao et al. 2006). These drugs 
seem to have also anti-oxidative, -anti-coagulant and anti-thrombotic effects (Liao and Laufs 
2005; Ali et al. 2007). Direct anti-inflammatory effects may be partially explained by HMG-
CoA independent lymphocyte function-associated antigen (LFA)-1 inhibition on T cells
(Weitz-Schmidt et al. 2001), important for lymphocyte adhesion and activation (Schramm et 
al. 2007; Takahashi et al. 2007). Statins maintain vascular homeostasis by regulating its 
cytoskeletal rearrangement, growth factor release and reactivity at the site of injury
(Hernandez-Perera et al. 1998; Alber et al. 2002; Undas et al. 2006; Lee et al. 2011). This 
involves inhibition of stress fibre formation of endothelial and perivascular supporting cells 
and endothelial exocytosis of VEGF and Weibel-Palade body factors via the family of Rho 
GTPases, and KLF2 (Takemoto and Liao 2001; Yamakuchi et al. 2005; Ho et al. 2008; van 
Agtmaal et al. 2012; Hilbert et al. 2013). Inhibition of blood clotting and thrombosis may be 
explained both by direct and indirect mechanisms. Statins reduce endothelial and macrophage
tissue factor (TF) expression and secretion of von Willebrand factor (vWF), and induce 
thrombomodulin expression RhoA and KLF2 -dependently (Colli et al. 1997; Szczeklik et al. 
1999; Undas et al. 2001; Eto et al. 2002; Masamura et al. 2003), and have effects on platelet 
activation (Sanguigni et al. 2005; Pignatelli et al. 2012). Furthermore, statins contribute 
indirectly to hemostasis and thrombosis via reduced vascular injury and inflammation.
Despite the relatively comparable lipid-lowering potency of statins, their ability to exert 
extrahepatic pleotropic effects differs largely due to dissimilar pharmacokinetic properties, 
mostly of lipophilicity qualities (Schachter 2005; Mason et al. 2005; Bonsu et al. 2013).
Pre- and postoperative treatment in cardiac and kidney ischemia-reperfusion
Pre- and early postoperative use of statins is associated with improved cardiac and kidney 
function after major elective surgery (Pan et al. 2004; Pasceri et al. 2004; Welten et al. 2008;
Kulik and Ruel 2009; Ege et al. 2010; Billings et al. 2010; Molnar et al. 2011, , Brunelli, 
2012 #568; Kuhn et al. 2013; Singh et al. 2013). Moreover, findings on the cardio- and 
renoprotective effects of statins are supported by acute preoperative statin administration 
before elective surgery in clinical trials in patients undergoing percutaneous coronary 
intervention (PCI) (Patti et al. 2007; Di Sciascio et al. 2009; Gibson et al. 2009; Patti et al. 
2011) and coronary artery bypass grafting (CABG) (Mannacio et al. 2008; Ji et al. 2009;
Antoniades et al. 2010; Sun et al. 2011; Baran et al. 2012). However, a current meta-analysis 
of randomized controlled trials including participants undergoing various cardiac surgical 
procedures challenges these conclusion by stating that preoperative statin treatment shortens 
the intensive care unit (ICU) and total hospital stay without affecting perioperative mortality, 
cardiovascular adverse events, or renal failure (Liakopoulos et al. 2012).
 
Based on the clinical experience, it is reasonable to administrate statins with 
immunosuppressive medication to reduce allograft vasculopathy and cardiovascular mortality
in heart transplant recipients (Kobashigawa et al. 1995; Katznelson and Kobashigawa 1995;
Weis and von Scheidt 1997; Wenke et al. 1997; Wenke et al. 2003; Kobashigawa et al. 2005).
Kidney transplant recipients benefit from statins against cardiovascular mortality (Jardine et 
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al. 2004; Holdaas et al. 2005; Navaneethan et al. 2009) and general mortality (Wiesbauer et 
al. 2008). The findings have been contradictory whether early statin use in combination with 
conventional immunosuppression affects the incidence and intensity of acute and multiple 
rejections episodes (Katznelson et al. 1996; Holdaas et al. 2001), and late graft survival in 
kidney transplant patients (Seron et al. 2008; Younas et al. 2010).
Organ donors do not have major cardiovascular disease nor tend to have previous medical 
track record of statin use. Donor treatment is a fascinating approach to prophylactically target
TX-IRI induced microvascular injury and induction of allograft immunogenicity. Preclinical 
studies have shown that rapid direct vasculoprotective and anti-inflammatory effects of 
statins (van Nieuw Amerongen et al. 2000; Wei et al. 2005; Zeng et al. 2005; Geissler et al. 
2006; Yasuda et al. 2006; Kircher et al. 2008; Tuomisto et al. 2008; Chen et al. 2008) could
be exploited in transplantation settings by donor treatment to reduce ischemia-reperfusion in 
cardiac and renal allografts (Table 6). All of those studies, however, unfortunately lack data 
on clinically relevant major injuries caused by brain death, cold and warm ischemia, or 
alloimmune response, or do not fit with the clinically relevant pretreatment time windows.
Thus, conclusions drawn from these studies are difficult to equal with the human 
transplantation setting. In the future, randomized clinical trials will hopefully answer whether 
vasculoprotective and anti-inflammatory properties of statins could be exploited in multiple 
organ donors to improve the quality of transplants and expansion of the donor pool. 
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Table 6. Previous literature of statin pretreatment in kidney IRI, and donor treatment in cardiac and kidney 
transplantation.
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Vascular growth factors
Ischemia-reperfusion injury (IRI) may lead to microvascular dysfunction and parenchymal
injury with deleterious consequences for allografts (Salahudeen et al. 2004; Tanaka et al. 
2005). Vascular growth factors have a regulatory role in these events. Vascular growth factor 
signaling mediates neointimal formation and exacerbates chronic rejection in cardiac 
allografts (Lemstrom and Koskinen 1997; Lemstrom et al. 2002), but on the other hand it 
may exert vascular stabilizing and anti-apoptotic actions in the allograft through endothelial-
pericyte and endothelial-cardiomyocyte crosstalk. The balance between these potentially 
harmful and beneficial actions determines the final outcome of the allograft.
Platelet-derived growth factor in cardiac allograft acute and chronic rejection
Platelet derived growth factor (PDGF) ligands and their receptors are part of a family of 
vascular growth factors that guide physiological mesenchymal cell functions during 
embryogenesis, angiogenesis and wound healing (Ross et al. 1990a; Battegay et al. 1994;
Leveen et al. 1994; Bostrom et al. 1996; Uutela et al. 2001; Uutela et al. 2004). In addition to 
physiological effects, PDGF has a regulatory role in several pathological conditions such as 
arteriosclerosis, rheumatoid and fibroproliferative diseases and tumor growth (Ross 1993;
Lokker et al. 2002; Ponten et al. 2003; Ponten et al. 2005; Schermuly et al. 2005). Functional 
differences of PDGF ligands are mediated by their unique receptor-binding affinity, ability to 
bind to extracellular matrix (ECM), and activation-dependence by proteases (Raines et al. 
1992; Fredriksson et al. 2004). Studies with knock-out mice suggest that in embryogenesis, 
PDGF-AA and -CC are the principal ligands responsible for PDGFR-? signaling, whereas 
PDGF-BB, and PDGF-DD to a lesser extent, for that of PDGFR-? (Li et al. 2000; Bergsten et 
al. 2001; Betsholtz et al. 2001; Ding et al. 2004). Divergent from homodimeric PDGF-AA and 
-BB, PDGF-AB has high affinity both to PDGFR-???and -????but not -???(Seifert et al. 
1993)?
In rat cardiac allografts, PDGF ligands and their receptors are significantly induced during the 
first postoperative week (Sack et al. 2004). Administration of PDGF-A, -C, and -D provoked 
pathological coronary intimal and myocardial fibroproliferation (Mancini and Evans 2000;
Tuuminen et al. 2009). In heart transplantation model with minimal ischemia alloimmune 
activation was reduced with imatinib mesylate, a potent inhibitor of PDGF receptor activity 
(Sihvola et al. 1999; Buchdunger et al. 2002; Sihvola et al. 2003; Nykanen et al. 2005).
Administration of imatinib mesylate also reversed advanced pulmonary vascular neointima 
formation and reduced carotic artery stenosis by inducing vascular smooth muscle cell 
(vSMC) apoptosis (Leppanen et al. 2000; Schermuly et al. 2005).
During hypoxia and metabolic compromise, PDGF-AB and -BB ligands play a pivotal role in 
microvascular and cardiomyocyte survival, endothelial repair, vascular stability and inhibition 
of inflammation, and cardiomyocyte contractile function (Kodama et al. 2001; Edelberg et al. 
2002; Xaymardan et al. 2004; Langley et al. 2004; Hsieh et al. 2006a; Hsieh et al. 2006b;
Zymek et al. 2006; Vantler et al. 2010; Kim et al. 2011; Fuxe et al. 2011). Blockade of PDGF 
receptor signaling abrogated PDGF-B-dependent survival and induced the activation of 
procaspase-3 and apoptosis of microvascular endothelial cells (Langley et al. 2004). Previous 
 29 
clinical observations have shown that PDGF receptor inhibition is associated with heart failure 
(Kerkela et al. 2006; Chu et al. 2007). Furthermore, previous reports have shown that 
activation of survival pathways in hypoxia is PDGF-B/PDGFR-? dependent (Zhang et al. 
2003). PDGF-BB pretreatment protected also neurons from toxicity-induced and lung 
fibroblasts from starvation-induced apoptosis (Tseng and Dichter 2005; Cartel and Post 2005).
Nevertheless, prolonged upregulation of PDGF-B may contribute to fibroproliferation and 
neointimal formation by recruiting mesenchymal cells, and enhancing their proliferation and 
survival (Ross et al. 1990b; Golden et al. 1991). 
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AIMS OF THE STUDY
The aim of the study was to investigate the underlying molecular mechanisms and functional 
parameters of microvascular dysfunction in cardiac and renal allografts during ischemia-
reperfusion injury. Furthermore, we aimed to target ischemia-reperfusion injury in cardiac 
and renal allografts with vasculoprotective simvastatin and immunomodulatory 
methylprednisolone using a clinically relevant donor treatment protocol.
The specific aims of the study were:
1) to characterize the effect of cold preservation and warm ischemia on microvascular 
dysfunction in the heart and kidney in the rat
2) to define the pharmacokinetics of simvastatin in the rat and in the human brain-dead 
organ donors
3) to compare simvastatin treatment of donors, recipients, or both donors and recipients
in rat cardiac and renal allografts
4) to investigate the class effect of statins (HMG-CoA reductase inhibitors), the dose-
response and the impact of different preservation solutions in rat cardiac allografts
during IRI
5) to target the preservation, IRI, acute and chronic rejection in rat cardiac and kidney 
allografts by donor simvastatin treatment
6) to clarify the exact role of different cell types in mediating the protective effects in rat 
cardiac and kidney allografts by donor simvastatin treatment
7) to dissect the vasculoprotective mechanisms of rat donor simvastatin treatment by 
pharmacological inhibition and supplementation of specific signaling pathways
8) to pursue dual vasculoprotective and immunomodulatory management of rat cardiac 
allografts by combined donor simvastatin and methylprednisolone treatment
9) to evaluate the expression of PDGF receptors and ligands in rat cardiac allograft acute 
and chronic rejection 
10) to study exogenous expression of PDGF ligands on rat cardiac allograft chronic 
rejection
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MATERIALS AND METHODS
1. Experimental procedures
Specific, pathogen-free, inbred male Wistar Furth (WF, RT1u) and Dark Agouti (DA, RT1a)
rats (Scanbur, Sollentuna, Sweden) weighing 300–350 g were used. The rats received regular 
rat food and tap water ad libidum, and were maintained on a 12-h light/dark cycle. Permission 
for animal experimentation (ESLH-2007-07748/Ym-23 (H)) was obtained from the State 
Provincial Office of Southern Finland. The animals received good care in compliance with 
the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy 
of Sciences and published by the National Academy Press (ISBN 0-309-15400-6, revised 
2011).
Heart and kidney preservation. The rats were anesthetized with inhalational isoflurane and 
a midline abdominal incision was performed. The heart or right kidney was removed. Hearts 
were subjected either to no cold ischemia and no warm ischemia, or to 4-hour cold ischemia 
and no warm ischemia, or to 4-hour cold ischemia and 1-hour warm ischemia. Kidneys were
subjected either to no cold ischemia and no warm ischemia, or to 16-hour cold ischemia and 
no warm ischemia, or to 16-hour cold ischemia and 1-hour warm ischemia.
Renal artery clamping. The rats were anesthetized with inhalational isoflurane and a 
midline abdominal incision was performed. Either the right renal artery was clamped for 30 
minutes to appreciate ischemia of the clamped right kidney as well as the remote ischemia of 
the non-clamped contralateral left kidney, or both renal arteries were clamped for 30 minutes 
for the analysis of post-ischemic renal function and kidney injury. After clamp removal, the 
kidneys were inspected for recovery of blood flow and the abdomen was closed. The rats 
were administered 1 ml of saline and 0.15 mg/kg s.c. of buprenorphinum (Temgesic 0.3 
mg/mL, Schering-Plough, Kenilworth, NJ) for post-operative maintenance of fluid balance 
and pain relief, respectively.
Heterotopic heart transplantations. Intra-abdominal heterotopic heart transplantations were 
performed from specific pathogen-free fully MHC-mismatched inbred male Dark Agouti 
(DA, RT1av1) to male Wistar Furth (WF, RT1u) rats (Figure 5) and inbred male BALB/c 
(B/c, H-2d) to C57BL/6J (B6, H-2b) mice (Harlan, Horst, The Netherlands) 2-3 months of 
age. The donors were anesthetized with inhalational isoflurane and a midline abdominal 
incision was performed. After infusion of heparinized ice-cold PBS or Plegisol cardioplegia 
solution (Hospira, Inc., Lake Forest, Il) into the inferior vena cava of the heart donor, the 
vena cava and pulmonary veins were ligated with 6-0 silk and the pulmonary artery and aorta 
were cut 2 to 3 mm above their origin in the heart. After removal, allografts were left without 
hypothermic preservation or were preserved either in heparinized PBS or Plegisol 
cardioplegia solution at +4 °C for 0, 2 or 4 hours depending on the study model. Cardiac 
allograft recipients were anesthetized with isoflurane anesthesia (2-5%/l O2), and received 
buprenorphine 0.15 mg/kg s.c. for peri- and postoperative analgesia. A midline incision was 
made, and the aorta and pulmonary artery of the allograft were anastomosed to the abdominal 
aorta and inferior vena cava of the recipient, respectively. Warm ischemia occurring during 
heart transplantation was standardized to one hour. The allografts were harvested 5, 20 or 30 
minutes, 6 hours, or 10, 56 or 100 days after the transplantation or in an acute rejection model 
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when the allograft function was lost.
Figure 5. Rat heterotopic heart transplantation model in simvastatin treatment studies.
Heterotopic kidney transplantations. Intra-abdominal heterotopic kidney transplantations 
were performed from specific pathogen-free fully MHC-mismatched male Dark Agouti (DA, 
RT1av1) to male Wistar Furth (WF, RT1u) rats. The donor DA rats were anesthetized with 
inhalational isoflurane and a midline abdominal incision was performed. The donor kidney 
was perfused with 250 IU heparin in 5 ml ice-cold PBS and removed with a segment of aorta 
and vena cava. The kidney was preserved in +4oC PBS for 16 hours. The left native kidney 
was removed during the transplantation and the donor allograft aorta and vena cava were 
anastomosed end-to-side into heterotopic position of the recipient aorta and vena cava. The 
ureter was anastomosed end-to-end. Warm ischemia occurring during kidney transplantation 
was standardized to one hour. The allografts were harvested 5 minutes, 6 hours or 5 days 
after the transplantation.
2. Drug administration
Donor simvastatin and methylprednisolone treatment. Two hours before the heart and 
kidney preservation, induction of warm ischemia, or graft removal for transplantations the 
DA rats received either peroral simvastatin (0.5, 2.0 or 5.0 mg/kg; Merck Research 
Laboratories, Whitehouse Station, NJ), peroral pravastatin (5.0 mg/kg; P4498 pravastatin 
sodium salt, Sigma-Aldrich, St. Louis, MO) or intravenous methylprednisolone (15.0 mg/kg;
Pfizer Inc., New York, NY) as a single dose. Simvastatin was diluted with polyethylene 
glycol (PEG, molecular weight 300; Sigma-Aldrich) to a concentration of 1.5 mg/ml, and the 
control rats received PEG vehicle p.o. 
Recipient simvastatin treatment. The recipient rats were given peroral simvastatin (2.0
mg/kg) diluted with PEG to a concentration of 1.5 mg/ml 2 hours before reperfusion and 
daily thereafter (2 mg/kg/d), and the control rats received PEG vehicle daily p.o.
Cyclosporine A. To prevent severe episodes of acute rejection and to allow the development 
of an alloimmune response and moderate chronic rejection, allograft recipients in over 6-hour 
transplantation models excluding the acute rejection study were given cyclosporine A (CsA, 
Novartis, Basel, Switzerland) diluted with Intralipid (Fresenius Kabi, Bad Homburg, 
Germany). Carciac allograft recipients were treated with CsA 2.0 mg/kg/d s.c. for the first 7 
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days and 1.0 mg/kg/d thereafter, whereas the dose given to kidney allograft recipients was 1.5
mg/kg/d. 
Imatinib mesylate. To inhibit PDGF receptor activity, protein tyrosine kinase inhibitor 
imatinib mesylate (Gleevec®, Novartis, Basel, Switzerland) was diluted with saline to a 
concentration of 10 mg/ml and administered to the rat cardiac allograft donors 6 hours before
procurement and to the rat cardiac allograft recipients at the time of reperfusion and daily 
thereafter at a dose of 10 mg/kg i.p. Saline vehicle was given i.p. to the control cardiac 
allograft recipients.
Inhibition or induction of specific signaling pathways. To inhibit NOS activity, N-nitro-L-
arginine methyl ester (L-NAME; Sigma-Aldrich) was dissolved in drinking water which was 
changed every other day. Donor rats received the orally active L-NAME (~50 mg/kg/day) for 
4 days before allograft removal. To block HO-1 activity, zinc protoporphyrin (ZnPP; 
Porphyrin Products Inc., Logan, UT) was dissolved in 0.2M NaOH, adjusted to pH of 7.4, 
and diluted with 0.9% NaCl to a concentration of 1 mg/ml. ZnPP was administered i.p. (20 
mg/kg) to donor rats 2 hours before allograft removal. To supplement RhoA GTPase 
prenylation pathway, geranylgeranyl pyrophosphate (GGPP; Sigma-Aldrich) at a 
concentration ~1 mg/ml in methanol was administered i.p. (1 mg/kg) to donor rats 2 hours 
before allograft removal. To block specific PDGFR-? or -? receptor activity during allograft 
ischemia-reperfusion donor mice were treated one day before cardiac procurement with rat 
IgG (Sigma-Aldrich, St. Louise, MO) 800 ?g i.p. or rat anti-mouse PDGFR-? (IMC-3G3;
ImClone, New York, NY) or rat anti-mouse PDGFR-? (IMC-2C5; ImClone) neutralizing 
antibody 800 ?g i.p. 
Drug assay. After collection the blood samples were immediately centrifuged at 2000 rpm 
for 10 min at +4 °C and stored at -80 °C until further analysis. The blood concentrations of 
simvastatin lactone and simvastatin ?-hydroxy acid were measured by liquid 
chromatography-ionspray tandem mass spectrometry.
Lipid analysis. To analyze the effect of recipient simvastatin treatment on blood lipid levels, 
serum samples were collected during the cardiac allograft harvest at 8 weeks and stored at -
20°C until further analysis. The concentration of total cholesterol (TC), triglycerides (TG), 
low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were measured using the 
enzymatic colorimetric test (Roche Diagnostics Cholesterol CHOD-PAP method; Cat. no. 
1491458; Roche Ltd, Basel, Switzerland) and a biochemical analyzer (Hitachi Modular PP-
analyzer; Hitachi Ltd., Tokyo, Japan).
3. Kidney function and injury analysis
Renal function. Serum was collected and subsequently frozen at -20°C until further analysis 
of serum creatinine and urea nitrogen activities.
Albuminuria and urine flow rate. To estimate glomerular vascular leakage 30 minutes after 
warm ischemia, the 24-hour trough urinary albumin waste was analyzed in metabolic cages 
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for 3 consecutive days. Albumin concentrations were measured by photometry. Urine flow 
rate was calculated by the following formula: UFR = UV / T × BW, where UFR is the urine 
flow rate, UV is the urine volume, T is the time, and BW is the body weight of the rat.
Neutrophil gelatinase-associated lipocalin. As a biomarker for acute kidney injury, we used 
rat neutrophil gelatinase-associated lipocalin (NGAL). NGAL serum levels were estimated 
by ELISA using mouse monoclonal anti-NGAL antibody (ABS 039-08 from BioPorto 
Diagnostics A/S, Gentofte, Denmark) at 3 days after bilateral renal artery clamping or at 6
hours and 5 days after kidney transplantation. 
In Situ apoptosis detection. The analysis of kidney allograft apoptosis was based on 
Terminal deoxynucleotidyl-transferase (TdT)-mediated dUTP nick end-labeling assay 
(TUNEL). Paraformaldehyde-fixed paraffin sections were stained with an in situ apoptosis 
detection kit (CardioTACS™, 4827-30-K, Trevigen Inc., Gaithersburg, MD). TUNEL-
positive apoptotic nuclei were counted from four random fields of each quadrant of a renal 
cross section with 40x magnification, and the results are given as the mean number of 
positive cells per 1 mm2.
Acute tubular necrosis. Tubular damage was determined by a senior pathologist from 
paraformaldehyde fixed paraffin sections stained with hematoxylin and eosin and scored 
semiquantitatively (0 to 3) as follows: 0, no damage; 1, mild damage; 2, moderate damage; 
and 3, severe damage.
4. Cardiac function and injury analysis
Cardiac allograft function. Cardiac allograft function was estimated by daily abdominal 
palpation, and graded according to heart beat from 0 to 4: 0 minimal or no contractility (heart 
beat <30 bpm); 1, poor; 2, moderate; 3, impaired; and 4 normal. Allografts were removed 
when the grade fell to 0.
Myocardial ischemia. Pimonidazole hydrochloride (HP2-1000, Hypoxyprobe TM-1 Kit, 
Chemicon International, Temecula, CA) was used to determine the extent of ischemic areas 
of cardiac allografts after reperfusion. Pimonidazole binds to thiol-containing proteins 
specifically in hypoxic cells. After cardiac allograft reperfusion, pimonidazole hydrochloride 
(60 mg/kg) was injected to penile vein i.v. and cardiac allografts were harvested at five 
minutes for immunofluorescense evaluation of the hypoxic regions using a primary 
fluorescein (FITC)-conjugated mouse monoclonal antibody directed against pimonidazole 
protein adducts and a secondary mouse anti-FITC monoclonal antibody conjugated to
horseradish peroxidase (HRP).
Cardiac troponin T. The rat serum levels of cardiac troponin T (cTnT) were analyzed with 
the third generation troponin T test (Troponin T STAT, Roche Diagnostics), which shows 
cross-reactivity of 0.001% with TnT originating in skeletal muscle at a concentration of 2.000 
ng/ml. The functional sensitivity is 0.03 ?g/l and the lower detection limit 0.01 ?g/l. The 
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cTnT was measured by electrochemiluminescence immunoassay (ECLIA) on the Elecsys 
2010 immunoassay analyser (Roche Diagnostics) 6 hours after heart transplantation.
5. Histopathology
Immunohistochemistry and immunofluorescence stainings. Four ?m thick paraffin-
embedded or cryostat cross-sections were cut in series on glass slides, stained using the 
peroxidase ABC method (Vectastain Elite ABC Kit, Vector Laboratories, Inc., Burlingame, 
CA) and the reaction was revealed by 3-amino-9-ethylcarbazole (AEC, Vector Laboratories). 
The specimens were blocked with a 20-min incubation with 1.5% normal goat 
serum/phosphate-buffered saline (PBS), pH 7.40, followed by incubation with primary 
antibodies at optimal dilution at room temperature (RT) for 30 min (monoclonal antibodies) 
or at +4°C for 15 hours (polyclonal antibodies). The primary antibodies were diluted with a 
0.1% bovine serum albumine/PBS solution. After washing in PBS, endogenous peroxidase 
activity was blocked with 10-min incubation with 0.1% hydrogen peroxidase (30%)/PBS 
solution. With intervening washes in PBS, the specimens were further incubated with 
biotinylated antibodies in the PBS buffer at RT for 30 min; the avidin-biotinylated 
horseradish complex in the PBS buffer at RT for 30 min and the reaction was revealed by 
AEC. Counterstaining was performed using Mayer’s hemalum. Immunofluorescent stainings 
were performed using Alexa 568 red and Alexa 488 green (Promega, Madison, WI)
secondary antibodies and DAPI nuclear staining (VECTASHIELD Mounting Medium with 
DAPI; Vector Laboratories).
Hyaluronan (HA) was stained from paraffin sections using a specific biotinylated bHABC
hyaluronan binding complex, which contains the biotinylated G1 domain of aggrecan and a 
link protein, prepared from bovine articular cartilage in our laboratory, by avidin-biotin-
peroxidase detection (Vector Laboratories; 1:200 dilution) with 0.05% 3,3 -diaminobenzidine 
(DAB) (Sigma Chemical Co.) as described (Tammi et al. 1994). The specificity of the 
staining was controlled by digesting some sections with Streptomyces hyaluronidase in the 
presence of protease inhibitors before staining, or preincubating the bHABP probe with 
hyaluronan oligosaccharides. 
The mean densities of immunopositive cells and vessels were quantified with 400-fold 
magnification from four random fields of each quadrant of the cardiac and kidney cross 
sections, and are given as a total for 1 mm2. As the cross-sectional area of a kidney allograft 
may enlarge during tissue remodeling and formation of interstitial fibrosis, we aimed to 
estimate the absolute fibroproliferative activity by giving TGF-?1, anti-phospho-Smad2 and 
FSP-1 as immunopositive cell counts for total cross-sectional area. The area positive for 
HAS1, HAS2 and HA was measured with computer assisted imagining (Zeiss Axionvision 
4.4, Carl Zeiss International, Oberkochen, Germany). Ten photographs with 400-fold
magnification were taken from each sample and the average positive area of these ten 
measurements was used in statistical analyses. All analyses were performed in a blinded 
manner by two independent observers. For antibodies and dilutions used in the studies, please 
see Table 7.
Fibrosis. Cardiac fibrosis was determined in a blinded review by two observers from 
paraformaldehyde fixed paraffin sections stained with Masson’s trichrome and scored 
semiquantitatively (0 to 3) as follows: 0, no fibrosis; 1, mild fibrosis; 2, moderate fibrosis; 
and 3, severe myocardial fibrosis. 
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Vasculopathy. Cardiac allograft vasculopathy was determined from sections stained with 
hematoxylin-eosin and Resorcin-Fuchsin for internal elastic lamina using computer-assisted 
image processing (Zeiss Axiovision 4.4, Carl Zeiss International) and measuring the area 
between the internal elastic lamina and the vessel lumen. The percentage of arterial occlusion 
was determined as the ratio of neointimal area to internal elastic lamina area.
6. mRNA expression 
RNA isolation and reverse transcription. Total RNA was extracted using RNeasy Mini Kit 
(Qiagen, Hilden, Germany). Reverse transcription of mRNA was carried out from 100 ng 
total RNA using High-RNA-to-cDNA kit (Applied Biosystems Inc., Carlsbad, CA) in a total 
volume of 20 ?l. After completed reverse transcription, 40 ?l of PCR-grade water was added 
to each cDNA sample. Three ?l of each sample (corresponding to 5 ng total RNA) were used 
in each subsequent PCR reaction.
Quantitative real-time PCR. Real-time PCR reactions were carried out on a RotorGene-
6000 (Corbett Research, Hilden, Germany) using 2X DyNAmo Flash SYBR Green Master 
mix (Finnzymes, Espoo, Finland). The measurement of the PCR product was performed at 
the end of each extension period. Amplification specificity was checked using melting curve 
analysis. The number of mRNA copies of each gene of interest was calculated from a 
corresponding standard curve using the RotorGene software. The expression levels of mRNA 
were normalized against the housekeeping gene with the most stable expression as 
determined with GeNorm application (version 3.4). For primers used in the studies, please 
see Table 8.
7. Microvascular dysfunction
Transmission electron microscopy. For transmission electron microscopy, mid-axial 
myocardial and cortical samples were microdissected, fixed with 2.5% glutaraldehyde in 100 
mM phosphate buffer, pH 7.4, incubated at +25 °C for 2 hours and post-fixed with 1% 
buffered osmium tetroxide for 1 hour, dehydrated and embedded in epon at room 
temperature. The sections were post-stained with uranyl acetate and lead and examined with a 
Jeol EX1200 II transmission electron microscope (Jeol Ltd., Tokyo, Japan) operating at 
60kV. Cardiac interendothelial junctions were analyzed from 10-15 representative 
longitudinally cut microvascular vessels per each graft sample and the incidence of 
interendothelial gaps was quantified. Renal filtration barrier defects were quantified by the 
incidence of glomerular units comprising either detached endothelial cells or podocyte foot 
processes from glomerular basement membrane. Peritubular capillary gaps were quantified 
by the incidence of interendothelial tight junction loss. Images were acquired with an 
ES500W CCD camera (Gatan Corp., Pleasanton, CA).
Microvascular interendothelial gap detection. During heart removal, coronary arteries 
were perfused with 50 ?l of rhodamine-labeled Concavalin A lectin (red) (Vector
Laboratories) that binds to the vascular endothelium and 50 ?l of biotinylated Ricinus 
communis lectin (blue) (Vector Laboratories) that binds to the vascular basement membrane, 
both dissolved in 100 ?l of NaCl. Thereafter the hearts were predisposed to 4-hour cold 
preservation, subsequent 1-hour warm ischemia and then the cardiac allograft coronary 
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network was flushed with 200 ?l 1% PFA in 0.05M citrate buffer, pH 3.5. Cryostat sections 
were stained with streptavidin and fluorescent-dye conjugate Avidin 350 nm (blue) (Promega 
Corp.) to detect biotinylated Ricinus communis lectin in order to identify inter-endothelial 
barrier disruption.
Microvascular leakage. A modified Miles Assay was used to measure extravasation of 
plasma proteins from the microvasculature into the interstitial space of heart and kindey.
Immediately after reperfusion, the recipients were injected i.v. with Evans blue (Sigma-
Aldrich) diluted with 0.9% NaCl, at a concentration of 30 mg/ml, which was allowed to 
circulate for 5 minutes (kidney) or 30 minutes (heart), whereafter the vascular network was 
flushed with 5 ml of 1% PFA in 0.05M citrate buffer, pH 3.5. For quantification of 
extravasated Evans blue, 100 mg of myocardial or cortical tissue was dissolved in 500 ?l of 
formamide on a shaker at +60 °C for 24 hours. One hundred ?l of formamide containing 
dissolved Evans blue dye was pipetted into cuvettes and the absorbance was measured by a 
spectrophotometer at 610 nm wavelength. To localize leakage, 1 minute before heart removal 
the coronary arteries were perfused with 50 ?l of FITC-dextran 40 kD (green) dissolved in 
100 ?l of NaCl. At heart removal, the coronary network was flushed with 200 ?l 1% PFA in 
0.05M citrate buffer, pH 3.5. Extravasated FITC-dextran was localized from cryostat sections
by its autofluorescence. 
Magnetic resonance imaging. To assess tissue edema, we used magnetic resonance imaging 
(MRI) to analyze the transverse relaxation time (T2) value before heart transplantation or 
unilateral kidney clamping 4 hours after heart transplant reperfusion or 20 minutes after 
restoration of renal blood flow. The MRI studies were performed with a 4.7 T scanner 
(PharmaScan, Bruker BioSpin, Billerica, MA) using a 90 mm shielded gradient that is 
capable of producing maximum gradient amplitude of 300 mT/m with 80-?s rise time. A 
linear birdcage RF coil with an inner diameter of 60 mm was used. After a scout, T2-weighed 
fast spin echo (rapid acquisition with relaxation enhancement, RARE) sequence was used 
(TR/TEeff = 4200/55 ms, rare factor = 8, matrix size = 256 x 256, field-of-view = 30 × 30 
mm, 15 slices, slice thickness = 2 mm). The multi- spin multi-echo sequence (MSME), based 
on CPMG (Carr-Purcell Meiboom-Gill) spin echoes was used for the determination of T2 
[repetition time (TR) = 1500 ms, echo time (TE) = 11 - 220 ms and 20 echoes, number of 
averages = 2, matrix size = 256 x 192, field of-view = 70 x 70 mm, single slice with slice 
thickness = 2.0 mm, acquisition time = 9 min 36s]. The value of T2 was calculated by fitting 
the measured intensities to the exponential relaxation curve using the least-squares method.
Microvascular perfusion. Endothelium binding FITC-labeled Lycopersicon esculentum 
(Tomato) lectin (Vector Laboratories) was used to detect perfused vessels 5 minutes (kidney) 
or 30 minutes (heart) after re-establishment of circulation. Coronary arteries or the left renal 
artery were perfused with 50 ?l FITC- labeled Tomato lectin diluted with 150 ?l of 0.9% 
NaCl for 1 minute before removal of the hearts and kidneys for fluorescence microscopy 
analysis. The number of FITC+ microvascular vessels from mid-axial cryostat cross sections 
was analyzed by fluorescence microscopy by counting positive capillaries from four random 
fields of each quadrant of the cross section with 400-fold magnification, and is given as a 
total for 1 mm2.
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Laser Doppler monitoring. Tissue perfusion was analyzed by dynamic measurement with 
laser Doppler monitor, Transonic BLF21-Series (Transonic Systems Inc., Ithaca, NY). The 
moving Doppler effect was calculated via a 18 gauge (1.2 mm) probe head receiving fiber 
optic light reflected by stationary structures within the tissue as well as by moving particles 
(red blood cells). A low intensity beam of monochromatic light was emitted to the portion of 
myocardial or cortical tissue, to 1mm depth, and the tissue volume under laser Doppler 
monitoring was approximately 1 mm3. The flow signal was sampled 200 s-1 from transmitted 
19200 baud (=pulses per second) and is represented as tissue perfusion units (TPUs) that are 
relatively proportional to ml/min/100g of tissue. Tissue perfusion was analyzed before heart 
transplantation or unilateral kidney clamping and continuously for one hour after heart 
transplant reperfusion or continuously for 30 minutes, and at 6 hours and 3 days after 
restoration of renal blood flow. 
The enzyme-linked immunosorbent assay (ELISA) of syndecan-1. For syndecan-1
measurements in serum samples, we used solid-phase ELISA kits (SEB966Ra, Design by 
Cloud-Clone Corp. Houston, TX, assembled by Uscn Life Science Inc., Cologne, Germany). 
The plates were analysed using the Bio-Rad microplate reader (Bio-Rad Laboratories, Inc.,
Hercules, CA) at a wavelength of 450 nm. Frozen (-20C) serum samples were thawed and 
shortly spinned. 100?l of standard, blanco, and diluted samples (1:8 in 0.01M PBS) was used 
per well. Standard curves were constructed by plotting the concentration and mean 
absorbance at 450 nm. To calculate the concentration, the standards were fitted with a 
second-order polynomial equation.
8. Gene transfer
Production of recombinant AAV2 vectors and their in vitro expression analysis. The 
coding regions of the PDGF cDNAs were cloned into the psub-CMV-WPRE AAV2 
expression vector. The rAAVs were produced with the two-plasmid transfection method as 
described. The titers of the recombinant AAVs were 5x1011-1012 genomic particles/ml. The 
expression of the recombinant proteins was verified by metabolically-labeled 293T cells 
transduced with the rAAVs. The expression of the proteins was analyzed by co-precipitation 
with the respective receptor-Ig molecules and the resultant protein complexes were separated 
in SDS-PAGE.
AAV2–mediated human PDGF-A-D gene transfer. After harvesting, coronary arteries of 
the donor rat heart were perfused through the aorta with 200 ?l of recombinant human 
AAV2-PDGF-A, -B, -C or -D (1.0x1011 gp) genes or AAV2 encoding EGFP (1.0x1011 gp) as 
a control gene, and 50 ?l of 10-7 mol/L acetylcholine to permeabilize the endothelium. 
AAV2-mediated human PDGF-A-D transgene expression in rat cardiac allografts was 
confirmed by a construct specific forward primer (5'-GGATGTTGCCTTTACTTCTAGG-3') 
and backward primers specific for human PDGF-A (5'-AATGACCGTCCTGGTCTTGCAG-
3'), PDGF-B (5'-CTCGGCCCCATCTTCCTCTCC-3'), PDGF-C (5'-
TGCTTGGGACACATTGACAT-3'), and PDGF-D (5'-ACAGCCACAATTTCCTCCAC-3'). 
The relative intensity of AAV2-EGFP transgene expression was determined from allograft 
midline cross sections using computer-assisted image processing (Zeiss Axiovision 4.4, Carl 
Zeiss GmbH).
Adenovirus-mediated human PDGF-BB gene transfer. Replication-deficient E1-E3-
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deleted human clinical grade (first generation, serotype 5) adenoviruses were produced under 
GMP conditions in 293T cells and analyzed to be free from contaminants (Makinen et al. 
2002). After allograft procurement, coronary arteries of the donor rat heart were perfused 
through the aorta with 200 ?l of adenoviruses encoding ?-Galactosidase marker gene (LacZ) 
(1.0x109 pfu / ml) or recombinant human full-length (carrying retention motif) PDGF-BB
(1.0x109 pfu / ml) under control of the cytomegalovirus (CMV) promoter. Transgene 
expression was confirmed by immunohistochemical staining of ?-galactosidase marker gene 
and quantitative PCR of human PDGF-B mRNA expression in allografts. 
9. In vitro assays
EC and SMC gene expression. Human cardiac microvascular endothelial cells (HMVEC-C) 
were cultured in EGM-2 MV growth medium. The cells used for the experiments were 
between passages 4-8. Rat coronary artery SMC (kindly provided by Dariusz Leszczynski; 
Finnish Centre for Radiation and Nuclear Safety, Helsinki, Finland) were cultured in 5% fetal 
calf serum. Simvastatin was dissolved in EtOH and activated by treatment with NaOH 
followed by neutralization to pH 7. HMVEC-C and rat coronary artery SMC were 
supplemented with activated simvastatin at a concentration of 1.0 ?M for 72 hours. RNA 
isolation and real-time RT-PCR analysis were performed as described above. 
TGF-?1-induced endothelial-to-mesenchymal transition in human cardiac 
microvascular endothelial cells. TGF-?1 was used to induce EndMT in HMVEC-C at a 
concentration of 10 ng/ml. Simvastatin was dissolved in EtOH and activated by treatment 
with NaOH followed by neutralization to pH 7 and concentrations of 0.1, 0.5 and 1.0 ?M
were used to inhibit EndMT. Antibodies used in in vitro studies were CD31 (ab9498, 
Abcam), ZO-1 (61-7300, Invitrogen, Carlsbad, CA) and Calponin (C2687, Sigma-Aldrich). 
HMVEC-C and EGM-2 MV growth medium were from Lonza, Basel, Switzerland. The cells 
used for the experiments were between passages 4-8. For immunofluorescence microscopy 
the cells were grown on glass coverslips for the indicated times. Coverslips were then washed 
three times with PBS, and the cells were fixed in ice-cold methanol at -20 °C. After washing 
three times with PBS, the cells were incubated in Dulbecco's PBS containing 3% BSA to 
prevent nonspecific binding of the antibodies. The cells were then incubated with the primary 
antibody in Dulbecco's PBS for 1 hour. The bound antibodies were detected using Alexa 
Fluor-594 secondary antibodies (Molecular Probes, Invitrogen). The coverslips were finally 
washed in water, mounted on glass slides using Vectashield anti-fading reagent (Vector 
Laboratories) and examined under an Axioplan 2 imaging microscope (Zeiss) using a 40x 
objective. Images were acquired with an AxioCamHRm camera and Axiovision 4.6 software 
(Zeiss) at the Molecular Imaging Unit of the University of Helsinki. For RNA isolation and 
real-time RT-PCR analysis, RNeasy mini kit (Qiagen) was used to isolate total cellular RNA. 
Reverse transcription was carried out with random hexamer primers (Invitrogen) and 
Superscript III reverse transcriptase (Invitrogen) using 1.0 ?g of total RNA according to the 
Manufacturer's instructions. The cDNAs were amplified using TaqMan Assays-on-Demand 
gene expression products (Applied Biosystems) and GeneAmp 7500 Sequence Detector 
thermal cycler (Applied Biosystems). Control amplifications directly from RNA were 
performed in order to rule out DNA contamination. The levels of gene expression were 
determined using the Ct method and the results are shown as mRNA expression levels 
normalized to the levels of a gene with a constant expression (TBP, tata binding protein). 
SDS- PAGE and immunoblotting were performed after the cells were lysed in RIPA buffer. 
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Equal amounts of protein were separated by SDS-PAGE under reducing conditions using 4-
20% gradient Tris-glycine gels (Lonza). The proteins were transferred to Protran 
nitrocellulose membranes (Whatman plc., Kent, United Kingdom) using a semi-dry blotting 
system (BioRad, Hercules, CA).
Weibel-Palade body exosytosis in human blood endothelial cells. Human dermal blood 
endothelial cells (BEC, PromoCell GmbH, Heidelberg, Germany) were cultured on 
fibronectin coated plates for 24-48 hours, changed to new growth media (PromoCell) and 
transferred to hypoxia (1% O2) or normoxia. Simvastatin was dissolved in EtOH and 
activated by treatment with NaOH followed by neutralization to pH 7 and a concentration of 
1.0 ?M was used to inhibit the secretion of Weibel-Palade body factors Ang-2 and ET-1. The 
growth media was collected at 24 hours. No apparent membrane disruption or cell death was 
observed by controlling cover slip cell counts at the end of the experiments and by using 
DAPI nucleic acid stain. ELISA (Quantikine-R&D Systems, Minneapolis, MN) was used to 
detect the presence of human angiopoietin-2 (DANG20) and human endothelin-1 (DET100)
in BEC growth media. The growth media was diluted at 1:5.
Allogenic mixed leukocyte culture and ELISpot. Resident peritoneal macrophages were 
isolated from DA rats by injecting 10 ml sterile PBS (Ca2+ and Mg2+ free) and 10 ml air into 
the peritoneal cavity followed by gentle massage of the abdomen. Abdominal skin was cut 
and the resulting peritoneal fluid collected. The cells were centrifuged at 400 × g at +4°C for 
10 minutes, washed once with PBS, dissolved in sterile water for 15 seconds to lyse any 
contaminating erythrocytes, and finally, the cell pellet was taken up in DMEM (10% fetal 
calf serum, 1% penicillin-streptomycin, and 1% glutamine). 1 × 10^6 macrophages were 
plated on 96-well cell culture plates in culture medium and allowed to adhere for 2 to 4 hours. 
Nonadherent cells were washed off with PBS, and new culture medium was added.
Splenocytes (T cells) were isolated from the spleen of WF rats with mechanical 
homogenization. The cell suspension was gravity-filtered through a 70-mm nylon mesh (BD 
FalconTM, San Diego, CA) to remove large debris. The cell suspension was centrifuged at 
400 x g for 10 minutes in the cold, dissolved in sterile water for 15 seconds to lyse any 
contaminating erythrocytes, and finally, the cell pellet was taken up in culture medium. The 
cells were cultured at 2 × 10^5 cells per well on 96-well cell culture plates with previously 
isolated macrophages in DMEM. After 5 days of culture the wells were counted and diluted 
to concentrations of 60 000 cells / ml for the subsequent ELISpot analysis.
The cells were centrifuged at 400 x g for 5 minutes and resuspended in DMEM (10% fetal 
calf serum, 1% penicillin-streptomycin, and 1% glutamine). IFN-? ELISpot (3220-2AW-
Plus, Mabtech, Nacka Strand, Sweden) was performed according to the Manufacturer’s 
instructions. 1.0 x 10^4 cells (n=3/group) were plated per well and incubated for two hours at 
+37°C with 5% CO2. Anti-CD3 stimulation was used to assure the viability of the cells and 
native and syngenic cells were used as negative controls (n=3/group). The spots were counted 
with the ELISpot-reader (BIO-SYS-GmbH, Karben, Gemany).
10. Statistics
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All data are given as mean ± SEM or as box plots showing the upper extreme (excluding 
outliers), upper quartile, median, lower quartile, and lower extreme (excluding outliers) 
where the outliers are shown as circles outside the box or as scatter plot showing mean and 
analyzed with SPSS 15.0 (SPSS Inc., Somers, NY). In non-parametric comparison, Mann-
Whitney U test was used for two-group comparison and Kruskall-Wallis with Dunn test when 
multiple groups were compared to control. Dunn post hoc test was applied only if Kruskall-
Wallis test demonstrated an overall statistically significant difference. In parametric 
comparison, Student’s t-test was used for two-group comparison and ANOVA with Dunnett´s 
correction for multiple group comparison. For comparison in a longitudinal study, data was 
analyzed by repeated-measures ANOVA. Linear regression analysis was applied to evaluate 
the relation of different simvastatin concentrations to the expression of mesenchymal genes in 
vitro. For survival Kaplan-Meier with Log-rank (Mantel-Cox) was applied. P<0.05 was 
considered as statistically significant.
 42 
Table 7. Antibodies used in the study
Anti-rat primary antibodies Dilution Product name Manufacturer
alpha-SMA 1:5000 A2547 Sigma-Aldrich
(p)Adducin (T445) 10 mg/ml ab58485 Abcam
?-galactosidase 1 ?g/ml MON5013 Sanbio V.B
CD4 5 mg/ml 22021D BD Pharmingen
CD8 5 mg/ml 22071D BD Pharmingen
CD42b (GPIb) 1:100 NCL-CD42b Novocastra
CD44 1:4000 BBA10 R&D systems
CD61 (GPIIIa) 1:100 NCL-CD61-308 Novocastra
CD161a ????/ml 555006 BD Pharmingen
ED1 5 mg/ml 22451D BD Pharmingen
(p)Ezrin (Thr567)/Radixin (Thr564)/Moesin (Thr558) 7.4 mg/ml #3141 Cell Signaling Technology
GFP 1:1000 ab290 Abcam
HAS1 2 mg/ml sc-34021 Santa Cruz
HAS2 2 mg/ml sc-34067 Santa Cruz
HAS3 2 mg/ml sc-34204 Santa Cruz
HIF-1alpha ?????? ? IMG629 Imgenex
(p)HMG-CoA Reductase (Ser872) 10 mg/ml 07-457 Upstate
KIM-1 8 mg/ml AF3689 R&D systems
(p)MLC2 (Thr18/Ser19) 2.1 mg/ml #3674 Cell Signaling Technology
Myeloperoxidase 20 mg/ml ab9535 Abcam
NG2 ?????? ? ab50009 Abcam
OX-62 10 ?g/ml MCA 1029G Serotec
PDGFR-? ????? ? sc-338 Santa Cruz
PDGFR-? ????? ? sc-339 Santa Cruz
PDGF-A ????? ? sc-7958 Santa Cruz
PDGF-B ????? ? sc-7878 Santa Cruz
PDGF-C 2.5 ?g/ml AF1447 R&D systems
PDGF-D 5 ?g/ml AF1159 R&D systems
Prolyl-4-Hydroxylase beta 2 mg/ml AF 5110-1 Acris
RECA-1 50 ?g/ml MCA97 Serotec
S100A4 (FSP-1) 1:100 A5114 DakoCytomation
(p)Smad2 (Ser465/467) 2.5 mg/ml AB3849 Millipore
TGF-beta1 2 mg/ml sc-146 Santa Cruz
Tropomyosin ????? ? ab7785 Abcam
VCAM ????? ? MMS-141P Covance
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Table 8. Primer 5'-3' sequences used in the study
Gene Primer Sequence
Ang-1 fwd CCACATAGGAAACCAGAAGCAGAAC
rev GCACATACAGTTGTCGTTATCAGCG
Ang-2 fwd CGGCACAAACTCGGAAACTG
rev TCACTGGTCTGGTCCAAAATCTG
Arg-1 fwd ATTGTGAAGAACCCACGGTCTG
rev CCACCCAAATGACGCATAGG
Bax fwd TGATGGCAACTTCAACTGGGG
rev CCACAAAGATGGTCACTGTCTGC
bFGF fwd TCCAAGCAGAAGAGAGAGGAGTTG
rev TCCAGGCGTTCAAAGAAGAAAC
Biglycan fwd ATGGGAGCCTGAGTTTTCTGCC
rev CCTTGGTGATGTTGTTGGAGTGC
CCL2 (MCP-1) fwd GCTGTCTCAGCCAGATGCAGTT
rev TTCCTTATTGGGGTCAGCACAG
CCL4 (MIP-1?) fwd CCTTCTGCGATTCAGTGCTGTC
rev AGATTTGCCTGCCTTTTTTGG
CCL21 fwd CATCCCAGCAATCCTGTTCG
rev CTTTCTTCCCAGACTTAGAGGTTCC
CCR7 fwd TGGCTCTCCTGGTCATTTTCC
rev CTTGAAGCACACCGACTCATACAG
CD80 fwd TGCTGCTGGTTGGTCTTTTCC
rev CGGTGTATGGACTGCTCTTCAGAAC
CD83 fwd GCCTTATTCCTTGACAATCCAAAAC
rev GACCAGAGAGAAGAGCAACACAGC
CD86 fwd TTGGGAATCCTTTTCTCGGTG
rev TTTGAGCCTTTGTGAACGGG
CINC-1 (IL-8) fwd CAAACCGAAGTCATAGCCACACTC
rev TTGTCAGAAGCCAGCGTTCAC
eNos fwd TAGGGCTATGCGGCAAGCAG
rev CACTGAGGGTATCGTAGGTGATGC
ET-1 fwd AGTGTGTCTACTTCTGCCACCTGG
rev GCATCTGTTCCCTTGGTCTGTG
FoxP3 fwd GGAAGATGGCATTGACAAAAGC
rev TCTCCGCACAGCAAACAAGC
GATA-3 fwd CATTACCACCTATCCGCCCTATG
rev TTCACACACTCCCTGCCTTCTG
HAS1 fwd TACACGGCTTTCAAGGCACTGG
rev ACATCTCCTCCAACAGCACCTACC
HAS2 fwd ACTGGGCAGAAGCGTGGATTATGT
rev AACACCTCCAACCATCGGGTCTTCTT
HAS3 fwd CAAGTAGGAGGTGTTGGAGGAGATG
rev AACTGCTGAAGGAGGCTGTTGC
HIF-1? fwd GAACCCATTCCTCATCCATCAAAC
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rev TCTTCTGGCTCATAACCCATCAAC
HO-1 fwd CGCCTTCCTGCTCAACATTG
rev ATCTGGGATTTTCCTCGGGG
HSP27 fwd ACTCAGCAGCGGTGTCTCAGAG
rev CTGGAGGGAGCGTGTATTTCC
HSP70 fwd TGGGACATTCTGCCTATCAAGTTTC
rev TGAGAGAGTCGCAATAAAGCACG
IDO1 fwd TGCCTCCCATTCTGTCTTACGC
rev AAGCCTTTATCGCAGTCCCCAC
IFN-? fwd GCCATCAGCAACAACATAAGTGTC
rev AGAATCAGCACCGACTCCTTTTC
IL-1b fwd GCTATGGCAACTGTCCCTGAACTC
rev CGAGATGCTGCTGTGAGATTTGAAG
IL-2 fwd GCAGCGTGTGTTGGATTTGACTC
rev GAGATGATGCTTTGACAGATGGC
IL-6 fwd TTGTTGACAGCCACTGCCTTC
rev GAATTGCCATTGCACAACTCTTTTC
IL-10 fwd ACCCACTTCCCAGTCAGCCA
rev TGCCTTGCTTTTATTCTCACAGG
IL-12p35 fwd CCTTGGTAGCATCTATGAGGACTTG
rev CGCCGCTGTGATTCAGAGAC
IL-17 fwd CTCAAAGTTCAGTGTGTCCAAACG
rev TCTATCAGGGTCCTCATTGCGG
IL-23 fwd CACCAGTGGGACAAATGGATCTAC
rev GACCTTGGGGATCACAACCATC
iNOS fwd GATTTTTCACGACACCCTTCACC
rev GGTCCTCTGGTCAAACTCTTGGAG
KLF2 fwd GCACACTTGCAGCTACACCAACTG
rev GCAATGATAAGGCTTCTCACCTGTG
KLF4 fwd GTTCTCATCTCAAGGCACACCTG
rev TCGCACTTCTGGCACTGAAAG
MCP-1 fwd GCTGTCTCAGCCAGATGCAGTT
rev TTCCTTATTGGGGTCAGCACAG
MHC II (RT1Ba) fwd CCTGGGAAAGAAGGTGCGTG
rev CAAGGGAAGAGCAAGATGGGAG
MMP-9 fwd GCCCTGGAACTCACACAACG
rev GCACCGCTGAAGCAAAAGAG
NF-?B fwd CTACACTTAGCCATCATCCACCTTC
rev CTCCACCACATCTTCCTGCTTG
PDGFR-? fwd GGAGAGGTGAGAAACAAAGGCAT
rev ACCACGAACTCTCTGACCTGATG
PDGFR-? fwd AGACGTACAAATTGCTGAGCTGC
rev ACTCAGCTCCAGTACACGGACAG
PDGF-A fwd GACAAACCTGAGAGCCCATG
rev ATGTCACACGCCACGTACAT
PDGF-B fwd AGGTGTTCCAGATCTCGC
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rev GTCACTGTGGCCTTCTTG
PDGF-C fwd AGGTTGTCTCCTGGTCAAGC
rev AGGTTGTCTCCTGGTCAAGC
PDGF-D fwd TGTGGCAAAACCTGGATTCAAG
rev TGATGGAGAGTGATAGGACACCCC
Rac1 fwd ACCGTCTTTGACAACTATTCTGCC
rev TGGGAGTATTGGGACAGTGGTG
RhoA fwd GTCCATAGTCTTCAGCAAGGACCAG
rev CCCATAAAGCCAACTCTACCTGC
RORc fwd ATCAATGCCAACCGTCCTGG
rev TGGAGGTGCTGGAAGTCCTGTAG
T-box21 fwd CCAAGTTCAACCAGCACCAGAC
rev CATCCACAAACATCCTGTAATGGC
TGF-?1 fwd TGCTAATGGTGGACCGCAAC
rev CACTGCTTCCCGAATGTCTGAC
Tie-2 fwd GGCTTAGTTCTCTGTGGAGTCAGC
rev AAAGTCCCTTCCTATGGTGATGG
TLR-2 fwd GAGGTCTCCAGGTCAAATCTCAGA
rev ACACACACCAGCAGCATCACAT
TLR-4 fwd GCATTGTTCCTTTCCTGCCTG
rev AAATCCAGCCACTGAAGTTGTGAG
TNF-? fwd TCTTCTGTCTACTGAACTTCGGGG
rev TCCTCTGCTTGGTGGTTTGC
VEGF fwd GCACTGGACCCTGGCTTTACTG
rev TGGGCTTTCTGCTCCCCTTC
VEGF-C fwd TGTGTGTCCGTCTACAGATGTGGG
rev TGATTGTGACTGGTTTGGGGC
VEGFR-3 fwd CTGGCTGCTCGGAACATTTTAC
rev ATCAAAGATGCTCTCGGGGG
Ang-1 fwd CTGGGACAGCAGGAAAACAGAG
rev GCCACAAGCATCAAACCACC
Ang-2 fwd GACGGCTGTGATGATAGAAATAGG
rev GACTGTAGTTGGATGATGTGCTTG
eNOS fwd CGGGTCCTGTGTATGGATGAGT
rev GGAGATGCTGTTGAAGCGGA
ET-1 fwd CAGAGGAACACCTAAGACAAACCAG
rev AGGCTATGGCTTCAGACAGGC
HIF-1? fwd GGAACATTATTACAGCAGCCAGACG
rev CATCCATTGATTGCCCCAGC
HO-1 fwd CCAGGCAGAGAATGCTGAGTTCA
rev GGGAAGTAGACAGGGGCGAAGA
iNOS fwd TCTTGCCTGGGGTCCATTATG
rev TCCTTTGTTACCGCTTCCACC
Normal = rat primers; Italic = human primers; fwd = forward sequence; rev = reverse sequence
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RESULTS
1. Transplant ischemia-reperfusion injury in cardiac allograft results in rapid 
microvascular dysfunction and fibroproliferation (unpublished results)
In transplantation, Tx-IRI leads to microvascular injury, which is a major cause for primary 
or late graft dysfunction. Similar mechanisms that induce microvascular dysfunction are also 
behind endothelial-to-mesenchymal transition (EndMT) and fibroproliferation in cardiac and 
kidney allografts. Recent findings suggest that relatively high numbers of fibroblasts in 
kidney and cardiac allografts arise through local EndMT (Zeisberg et al. 2007; Zeisberg et al. 
2008). Interestingly, both microvascular permeability and EndMT, depend on endothelial 
cytoskeletal rearrangement, loss of endothelial-endothelial integrity and detachment from 
supporting basal lamina. Moreover, infiltration of peripheral blood mononuclear cell into 
allografts induces the expression of microvascular destabilizing and pro-inflammatory and 
pro-proliferative factors, e.g. HIF-1? and TGF-?1, which participate in endothelial barrier 
disruption and induce mesenchymal transition and fibrosis (Higgins et al. 2007; Li et al. 
2009; Qi et al. 2011).
To investigate the effect of cardiac allograft Tx-IRI on microvascular dysfunction and 
fibroproliferation, intra-abdominal heterotopic heart transplantations were performed between
fully MHC-mismatched rats. Cardiac allografts were subjected to 4-hour cold preservation, 
mimicking clinical organ transportation time. Warm ischemia occurring during heart 
transplantation was standardized to one hour that mimics warm ischemia during surgical 
procedure. Cardiac allografts were harvested five minutes after reperfusion to investigate 
microvascular permeability and perfusion disturbances. Further, recipients with 10-day 
follow-up were given CsA background immunosuppression to prevent severe episodes of 
acute rejection and to allow the development of alloimmune response. 
Profound vascular leakage was present at the sites of interendothelial gaps of cardiac 
allografts already five minutes after reperfusion (Figure 6A). In addition, hypoperfusion and 
myocardial ischemia were observed (Figure 6B). At 10 days after reperfusion, pathological 
fibroproliferation that possibly involved EndMT was present in the border zone of fibrotic 
areas in cardiac allografts (Figure 6C-D).
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Figure 6. (A) Immunofluorescence triple staining of cardiac allografts showed that the 4-h cold plus 1-h warm 
ischemia induces vascular leakage at the sites of endothelial barrier dysfunction revealed by leakage of FITC-
dextran 40 kD (green) around the endothelial-endothelial cell gaps (Risin Communis lectin; blue) in perfused 
microvascular vessels (Rhodamine-labeled Concavalin A lectin; red) already five minutes after reperfusion. (B1)
Hypoperfused areas co-localized with (B2) pimonidazole-positive ischemic myocardium five minutes after 
reperfusion. (C-D) We also noticed that p-Smad-2 immunoreactivity, indicating active TGF-?1 signaling and 
fibroblast specific protein (FSP)-1 and endothelial marker RECA-1 double-immunoreactivity, that may 
contribute to allograft fibrosis through EndMT, localized in cardiac allograft perifibrotic boarderline at 10 days. 
Arrowhead = fibrosis, arrow = perifibrotic boarderline, double arrow head = myocardiac with obvious 
microvascular network. Unpublished data.
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2. Donor simvastatin treatment targets microvasculature of the heart, kidney, and liver 
in the rat (I, II)
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are 
widely used for primary and secondary prevention of cardiovascular diseases. In addition to 
their lipid lowering ability, statins have beneficial pleiotropic microvasculoprotective effects. 
These drugs seem to have anti-inflammatory, -oxidative, and -thrombotic effects (Koh 2000;
Takemoto and Liao 2001). Statins may also attenuate the expression and secretion of 
angiogenic growth factors and microvascular activation at the site of injury (Undas et al. 
2006). To date, however, the role of statins in Tx-IRI in cardiac and kidney allografts remain 
poorly understood. 
In our study, we focused on the effects of donor simvastatin treatment on microvascular 
function. The rapid protective effects of statins could have novel clinical implications in 
organ transplantation where the time-window to treat a cadaveric organ donor is limited –
usually between 6 to 8 hours from the declaration of brain-death to organ procurement. After 
peroral administration, simvastatin is absorbed in the intestine, and the inactive lactone form 
is metabolized to the active ?-hydroxy acid form in the liver before proper HMG-CoA 
reductase inhibition is achieved in the target tissue.
To establish the clinical relevance of oral donor simvastatin treatment in the terms of 
adequate absorption and metabolism, we performed detailed pharmacokinetic analyses of the 
blood levels of the inactive and active simvastatin forms after (i) simvastatin 5 mg p.o. 
administration to rat donors and (ii) simvastatin 80 mg administration via nasogastric tube to 
brain-dead human organ donors. In both situations, simvastatin was absorbed and 
metabolized to the active ?-hydroxyl acid form within 2 hours, but the metabolism was more 
rapid in the rat than in man (Figure 7A-B). In the rat, the simvastatin doses were based on our 
dose response study. Immunohistochemical and immunofluorescense double-stainings 
revealed that the simvastatin target molecule HMG-CoA reductase was mainly found in the 
microvasculature of the heart (Figure 7C), kidney and liver in the rat (Tuuminen et al. 2013).
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Figure 7. (A) Pharmacokinetic analysis with liquid chromatography-ionspray tandem mass spectrometry 
showed that after rat single-dose peroral simvastatin 5.0 mg/kg administration, simvastatin lactone was absorbed 
rapidly within hours. (B) Simvastatin lactone was also absorbed within 2 hours in human organ donors after 
clinically-approved simvastatin 80 mg administration via nasogastric tube indicating the applicability of donor 
simvastatin treatment in a clinical situation. (A-B) Simvastatin lactone was hydroxylated to its active ?-hydroxy 
acid form and was eliminated much more rapidly in the rat than in human organ donors. (C) HMG-CoA 
reductase, a target molecule of statins, localized in donor hearts abundantly in the cardiac capillary network of 
non-transpanted rat hearts, but not in vSMC nor in cardiomyocytes, suggesting capillary network as the primary 
therapeutic target. (A-C) reprinted from Tuuminen R et al., Circulation 2011 Sep 6;124(10):1138-50 with the 
permission from the American Heart Association and Lippincott Williams and Wilkins (LWW).
3. Donor simvastatin treatment prevents microvascular activation and instability 
during cold and warm ischemic preservation of hearts and kidneys in the rat (I, II)
Cytoskeletal rearrangement of microvascular endothelial cells and their surrounding pericytes 
may lead to increased microvascular permeability, leukocyte extravasation, thrombosis, 
vasoconstriction, and compromised tissue perfusion. This may be mediated through stress-
fiber formation and also through the release of vasoactive factors such as angiopoietin (Ang)-
2 and endothelin (ET)-1 from endothelial Weibel-Palade bodies. Statins, on the other hand, 
have important pleiotrophic vasculoprotective effects mediated largely through the inhibition 
of important regulators of cell cytoskeleton and intracellular signaling pathways. Therefore, 
we studied phosphorylation of intracellular myosin light chain (MLC)2 in the vascular wall, 
Rho GTPase signaling and Ezrin/radixin/moiesin (ERM) family of actin-binding proteins that 
function as signal transducers in responses involving cytoskeletal rearrangement.   
Four-hour (heart) or 16-hour (kidney) cold preservation and additional 1-hour warm ischemia 
resulted in abundant vascular RhoA/ROCK activation indicated by immunoreactive 
phosphorylated adducin in capillaries, postcapillary venules, arterioles and arteries in the 
heart (Figure 8A-8C) and kidney (Figure 9B). Donor simvastatin treatment given 2 hours 
before the procurement prevented vascular RhoA/ROCK activation in the heart (Figure 8A-
8C) and kidney (Figure 9B). Furthermore, donor simvastatin-treated prevented vascular wall 
activity of other cytoskeletal rearrangement and stress fiber formation involved molecules 
MLC2 (Figure 9A) and ERM proteins in allografts.
Next, we studied the effects of donor simvastatin treatment on structural and molecular 
changes in the microvasculature. Ultrastructural analysis with transmission electron 
microscopy (TEM) revealed that 4-hour (heart) or 16-hour (kidney) cold preservation and 
additional 1-hour warm ischemia resulted in myocardial and peritubular capillary 
interendothelial gap formation, and glomerular endothelial and pericyte detachment from 
supporting glomerular basement membrane (Figure 8D and 9C). Donor simvastatin 
treatment, however, preserved myocardial capillary and peritubular and glomerular 
microvascular barrier integrity during cold and warm ischemia (Figure 8D and 9C) and 
prevented vascular permeability and perfusion disturbances that occur early after kidney 
allograft reperfusion. 
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Figure 8. (A-C) To determine whether cardiac 4-h cold and 1-h warm ischemia lead to RhoA/ROCK activation, 
we performed immunostainings for phosphorylated adducin (p-adducin) in native DA hearts or hearts subjected 
to 4-hour cold and 1-hour warm ischemia. Four-hour cold and 1-hour warm ischemia induced p-adducin 
immunoreactivity in RECA-1+ ECs, NG2+ ?????????? ???? ?-SMA+ smooth muscle cells of capillaries, 
postcapillary venules, arterioles, and arteries. (D) Microvascular EC-EC gaps (arrows) were determined by 
transmission electron microscopy of left ventricular longitudinally cut microvascular vessels. Transmission 
electron microscope analysis indicated that 4-hour cold and 1-hour warm ischemia markedly increased the 
incidence of microvascular EC-EC gaps. (A-D) Donor simvastatin treatment decreased p-adducin 
immunoreactivity in capillaries, postcapillary venules, and arterioles, as well as in the media of arteries, and 
decreased the formation of EC-EC gaps, indicating decreased RhoA/ROCK activation and enhanced endothelial 
stability. (A-D) reprinted from Tuuminen R et al., Circulation 2011 Sep 6;124(10):1138-50 with the permission 
from the American Heart Association and Lippincott Williams and Wilkins (LWW).
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Figure 9. (A-B) To determine whether kidney 16-h cold and 1-h warm ischemia lead to cell cytoskeleton 
signaling pathways, we performed immunostainings for phosphorylated myosin light chain (p-MLC)2 and 
phosphorylated adducin (p-adducin) in native DA kidneys or kidneys subjected to 16-hour cold and 1-hour 
warm ischemia. Sixteen-hour cold and 1-hour warm ischemia induced microvascular p-MLC2 and p-adducin 
immunoreactivity, both which were decreased by donor simvastatin treatment. (C) Glomerular filtration barrier 
defects were determined by transmission electron microscopy. Transmission electron microscope analysis 
indicated that 16-hour cold and 1-hour warm ischemia markedly increased the incidence of detachment of 
fenestrated endothelium and podocytes from glomerular basement membrane. Simvastatin maintained 
glomerular ultrastructure during cold and warm ischemia, and the fenestrae of the endothelium did not reach 
over 100 nm in most of the glomerular units. (A-C) reprinted from Tuuminen R et al., Am J Transplant. 2013 
Aug;13(8):2019-34 with the permission from the American Heart Association and Lippincott Williams and 
Wilkins (LWW).
4. Donor simvastatin treatment inhibits permeability and perfusion disturbances in IRI 
in a kidney artery clamping model (unpublished results)
As simvastatin reduced RhoA/ROCK signaling and preserved barrier integrity of 
microvascular network during prolonged cold ischemic preservation and warm ischemia, we 
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proceeded to study the effects of simvastatin pretreatment on IRI in non-allogenic and 
allogenic environment. First, we used a kidney artery clamping as a model for renal IRI. 
Single-dose peroral simvastatin treatment (5 mg/kg) 2 hours before renal 30-minute warm 
ischemia, maintained outer medullar T2 -weighted relaxation time in a clamped ischemic 
right kidney and also non-clamped contralateral left kidney 20 minutes after reperfusion 
(Figure 10A). Histological evaluation of the kidney at the 20-minute timepoint revealed 
intense intravascular congestion, capillaries filled with trapped erythrocytes in vehicle-treated 
control rats, but not in simvastatin-treated rats (Figure 10B). Further analysis using albumin-
binding Evans blue dye revealed that simvastatin treatment reduced vascular leakage 5 
minutes after reperfusion in a dose-dependent manner (Figure 11A). Endothelium-binding 
FITC-labeled tomato lectin perfusion confirmed poor post-ischemic blood flow 5 minutes 
after reperfusion in vehicle-treated kidneys (Figure 11B). Simvastatin treatment dose-
dependently improved peritubular capillary blood flow (Figure 11B). The effect of 
simvastatin on peritubular capillary blood flow was counteracted by RhoA supplementation 
with GGPP (Figure 11B), indicating that simvastatin regulates microvascular blood flow via 
inhibition of RhoA signaling pathway.  
Figure 10. DA rats were treated with simvastatin 2 hours before 30-minute right renal artery clamping. (A) 20 
minutes after reperfusion, non-invasive magnetic resonance imaging (MRI) analysis and (B) histological 
evaluation of H&E stained sections were performed to study signal intensities related to diffusion of water and 
fluids of T2-weighted images and their relationship to specific histopathologic tissue characteristics.
Unpublished data.
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Figure 11. DA rats were treated with simvastatin 2 hours before 30-minute right renal artery clamping. (A) To 
study vascular leakage, recipients were injected i.v. with albumin binding Evans blue immediately after 
reperfusion, which was allowed to circulate for 5 minutes. Extravasated Evans blue was quantified from 
myocardial tissue by spectrophotometer absorbance. (B) One minute before kidney removal the vascular 
network was perfused with endothelium binding FITC-labeled Lycopersicon esculentum (Tomato) lectin to 
detect perfused vessels during kidney removal at 5 minutes. Partially unpublished data.
5. Donor simvastatin treatment preserves tubular tight junctions and reduces tubular 
adhesivity in renal allografts during ischemia-reperfusion injury (unpublished results)
Next we studied whether donor simvastatin treatment with its direct vasculoprotective effects 
could have beneficial effects also at tubular level. Donor simvastatin treatment preserved 
expression of tubular junctional proteins ZO-1 and Occludin in kidney allografts and 
abrogated adhesion molecule P-selectin induction, when compared to non-treated kidney 
allografts (Figure 12).
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Figure 12. Kidney allograft donors were treated with single-dose peroral simvastatin (5 mg/kg) or control 
vehicle. Allografts were subjected to 16-h cold preservation and 1-h warm ischemia and transplanted to MHC-
mismatched recipients. Six hours after allograft reperfusion, tubular junction (ZO-1 and Occludin) and adhesion 
(P-selectin) proteins were evaluated by immunohistochemistry. Unpublished data.
6. Donor simvastatin treatment reduces myocardial and tubulointersitial injury in 
cardiac and renal allografts during transplant ischemia-reperfusion injury (I, II)
Statin medication is conventionally commenced after heart and kidney transplantation due to 
its cardiovascular protection and beneficial effects on chronic rejection and long-term 
survival (the Scandinavian Simvastatin Survival Study 1994; Kobashigawa et al. 1995; 
Shepherd et al. 1995; Heart Protection Study Collaborative 2002). However, previous 
observations from randomized clinical trials support the short-term effects of preoperative 
statin administration against IRI-induced cardiac and kidney cell damage in a cholesterol-
independent fashion when administered only hours or few days before elective intervention.
To evaluate Tx-IRI -induced myocardial and tubulointersitial damage in cardiac and kidney 
allografts, clinically used biomarkers such as cardiac troponin T (cTnT) and neutrophil 
gelatinase-associated lipocalin (NGAL) were applied. In the cardiac transplantation model, 
we treated the donor (5 mg/kg), the recipient (2 mg/kg), or both the donor and the recipient 
with simvastatin. Six hours after reperfusion, serum was collected for cardiac troponin T 
measurement. Prolonged 4-hour cold ischemia increased serum release of cardiac troponin T 
in allograft recipients, which was nearly prevented by donor, but not by recipient simvastatin 
treatment (Figure 13A). In the recipients of kidney allografts, 16-hour cold ischemia induced 
serum NGAL levels both in simvastatin and vehicle-treated control allograft at 6 hours 
(Figure 13B). However, the NGAL levels returned towards normal in the recipients with 
allografts from donors treated with simvastatin already at 5 days, indicating faster recovery 
from tubulointerstitial injury (Figure 13B). 
 
 55 
Figure 13. Cardiac allograft donors (5 mg/kg), recipients (2 mg/kg), or both donors and recipients, and kidney 
allograft donors (5 mg/kg) were treated with single-dose peroral simvastatin or control vehicle. (A-B) serum 
cardiac troponin T (cTNT) levels were analyzed 6 hours and neutrophil gelatinase-associated lipocalin (NGAL) 
levels 6 hours and 5 days after reperfusion to evaluate myocardial damage after heart transplantation and 
tubulointerstitial damage after kidney transplantation, respectively. (B) reprinted from Tuuminen R et al., Am J 
Transplant. 2013 Aug;13(8):2019-34 with the permission from the John Wiley & Sons, Inc.
7. Donor simvastatin treatment targets the expression of multiple genes involved in 
vascular homeostasis, fibroproliferation, and innate and adaptive immune reponses in 
cardiac and renal allografts in the rat (I-III)
Rat cardiac and renal allografts are predisposed to nonimmunological and immunological 
injuries during donor brain-death, cold ischemic preservation and warm ischemia, ischemia-
reperfusion injury, and during the activation of innate and adaptive immune responses after 
transplantation. These may alter the expression of a variety of genes involved in vascular 
homeostasis, cell survival, inflammatory and fibroproliferative responses including 
arteriosclerosis, interstitial fibosis, glomerular sclerosis, and tubular atrophy in allografts. 
Simvastatin treatment may have direct and indirect effects on the expression of these genes. 
Thus, we analyzed the effect of simvastatin treatment on the mRNA expression levels using 
quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) with in vivo
and in vitro models. In cardiac allografts subjected to 4-hour cold and 1-hour warm ischemia,
donor simvastatin treatment decreased the mRNA levels of Rho GTPases RhoA and Rac1 
and had an influence on genes involved in vascular homeostasis, such as HIF-1? and its 
downstream iNOS, VEGF, HO-1, and ET-1. In addition to quantitative real-time RT-PCR, 
donor simvastatin treatment significantly decreased nuclear HIF-1 immunoreactivity in 
cardiac allografts. In vitro analysis revealed that simvastatin treatment modulates mRNA 
levels of genes involved in vascular homeostasis through endothelial but not smooth muscle 
cells.
In kidney allografts with 16-hour cold and 1-hour warm ischemia, donor simvastatin 
treatment reduced the mRNA expression of Ang-2, a potent mediator of vascular 
destabilization and its receptor Tie-2, arginase-1, the enzyme that metabolizes a NO synthase 
substrate arginine, the pro-apoptotic BAX/Bcl-2 ratio, pro-fibrotic and vasoactive factors 
such as ET-1, PDGF-A and TGF-?1, tissue remodeling MMP-9, innate immune ligand HAS-
1, lymphangiogenic VEGF-C and VEGFR-3, and dendritic cell maturation markers CD80, 
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CD83 and CD86, and MHC class II 6 hours after reperfusion (Table 8), when compared to 
allografts from vehicle-treated donors. At 5 days, donor simvastatin treatment significantly 
downregulated the mRNA levels of transcription factor HIF-1?, its downstream iNOS and 
VEGF as well as innate immune response receptor TLR-2 and its downstream NF-?B (Table 
9).
Table 9. Quantitative real-time RT-PCR analysis of mRNA expression of genes involved in vascular 
homeostasis, fibroproliferation, and innate and adaptive immune reponses in renal allografts in the rat
             6 hours                              5 days
mRNA No treatment Simvastatin No treatment Simvastatin
Ang-1 1±0.09          0.67±0.06 * 1.33±0.12 1.35±0.10
Ang-2 1±0.13          0.56±0.17 ** 0.31±0.07 0.28±0.04
Arg-1 1±0.31   0.18±0.04 * 0.27±0.05          0.37±0.06
Bax/Bcl-2 1±0.08          0.71±0.08 * 0.79±0.05 0.82±0.06
CD-80 1±0.11          0.53±0.03 * 3.61±0.76 2.46±0.30
CD-83 1±0.07          0.66±0.10 * 1.40±0.08 1.76±0.15
CD-86 1±0.13          0.62±0.08 * 1.06±0.06 1.06±0.10
ET-1 1±0.10          0.64±0.07 * 0.37±0.03 0.40±0.04
HAS-1 1±0.15          0.56±0.11 * 0.09±0.01 0.10±0.02
HIF-1? 1±0.11 1.21±0.26 1.83±0.21          1.02±0.07 ***
iNOS 1±0.31 0.65±0.24 0.77±0.13          0.46±0.04 *
MHC II 1±0.13   0.53±0.09 * 8.15±1.35   5.97±0.48
MMP-9 1±0.22          0.34±0.05 * 0.91±0.22 0.99±0.13
NF-?B 1±0.14 1.07±0.12 2.07±0.21          1.33±0.11 *
PDGF-A 1±0.09          0.64±0.11 * 0.56±0.06 0.55±0.04
T-bet 1±0.07          0.73±0.09 * 15.88±1.84 12.88±0.92
TGF-?1 1±0.07          0.68±0.10 * 4.55±0.70 3.07±0.22
Tie-2 1±0.12          0.57±0.07 * 0.89±0.15 0.82±0.08
TLR-2 1±0.28 0.80±0.25 2.28±0.45          1.42±0.07 *
VEGF-A 1±0.76 1.29±0.12 0.95±0.12          0.56±0.03 *
VEGF-C 1±0.11          0.57±0.07 ** 0.61±0.08 0.82±0.04
VEGFR-3 1±0.11          0.54±0.09 ** 0.48±0.03 0.47±0.04
Donors were treated with simvastatin 5 mg/kg p.o. 2 hours before graft harvest. Kidney allografts were collected 
6 hours or 5 days after reperfusion for quantitative real-time RT-PCR. The results were normalized to 18S rRNA 
and are given as a ratio to mRNA in control allografts at 6 hours. Modified from Tuuminen R et al., Am J 
Transplant. 2013 Aug;13(8):2019-34 with the permission from the John Wiley & Sons, Inc.
The beneficial effects of donor simvastatin treatment on microvascular permeability in 
cardiac allografts and perfusion in cardiac and kidney allografts were mediated through nitric 
oxide (NO) and inhibition of the RhoA GTPase pathway, respectively ((Tuuminen et al. 
2011) and Figure 11B).
8. Donor simvastatin treatment inhibits chronic rejection and late graft loss of cardiac 
allografts in the rat (I, unpublished results)
The gradual development of allograft vasculopathy is one of the main reasons for the long-
term allograft failure. Allograft vasculopathy is characterized by concentric neointimal 
formation in the vasculature of the transplant. Among vasculopathy, chronic inflammation 
and fibroproliferation eventually lead to cardiac fibrosis and graft failure. Statin 
administration to the recipients delays the progression of allograft vasculopathy and reduces 
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the rate of graft failure both through its cholesterol-dependend and cholesterol-independent 
anti-inflammatory and anti-mitogenic effects (Kobashigawa et al. 1995; Wenke et al. 1997;
Wenke et al. 2003; Kobashigawa et al. 2005). Here we studied the effect of single-dose 
donor, daily recipient and combined donor and recipient simvastatin treatment on cardiac 
allograft inflammation, fibrosis, micro- and macrovascular alterations and graft survival. The 
allograft recipients were treated with suboptimal dose of CsA to avoid irreversible episodes 
of acute rejections but to allow the chronic low-level inflammation in allografts and the 
development of chronic rejection. Allografts were followed until the study end-point 56 days 
after transplantation. Donor or combined donor and recipient simvastatin treatment 
significantly reduced the densities of allograft infiltrating ED-1+ macrophage, MPO+
neutrophil and CD4+ T cell, and myocardial fibrosis. However, only combined donor and 
recipient simvastatin treatment significantly improved allograft survival, maintained the 
density of RECA-microvasculature in the myocardium, and reduced allograft vasculopathy 
56 days after the transplantation. The effect of simvastatin combination treatment on arterial 
occlusion was evident both in micro- (arterial occlusion percentage control vs. simvastatin 
combination treatment, diameter <50mm; 59.9% vs. 28.2%) and macrovessels (diameter 
>50mm; 54.3% vs. 28.0%, respectively, Figure 14).
Figure 14. Cardiac allograft donors were treated with single-dose simvastatin (5 mg/kg, p.o.) 2 hours before 
graft removal, recipients with single-dose simvastatin (2 mg/kg, p.o.) 2 hours before graft reperfusion and daily 
thereafter (2 mg/kg/d, p.o.), or simvastatin was given to both donors and recipients. CsA background 
immunosuppression was given to the cardiac allograft recipients as 2.0 mg/kg for 7 days and 1.0 mg/kg daily 
thereafter. To determine arterial occlusion of micro- and macrovessels in chronically-rejecting cardiac allografts
we performed morphometric analysis 56 days after transplantation. Arrows indicate neointimal area. Scale 
bars=50 ?m.. Partially unpublished data.
9. Persistent overexpression of PDGF-A, -C and -D induces cardiac allograft 
vasculopathy and fibrosis, whereas in ischemia-reperfusion injury PDGF-B prevents 
microvascular loss and PDGF receptor inhibition induces myocardial injury in rat 
cardiac allografts (IV, unpublished results)
Rat cardiac allografts subjected to chronic rejection in MHC-mismatched recipients were 
analyzed 56 days after transplantation. Chronic rejection induced intense PDGF ligands and 
receptors expression in the allograft coronary artery intima, with the exception of PDGF-B. 
To further elucidate the role of different PDGF ligands in cardiac allograft chronic rejection, 
we chose adeno-assosiated virus (AAV)-2 gene transfer and 100 day transplantation model, 
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to ensure stable and long-term transgene expression. AAV2-mediated gene transfer of PDGF-
A, -C, and -D, but not -B, orchestrated TGF-?1 mRNA upregulation (Fraser et al. 2003), and 
pathological fibroproliferative manifestations in the allografts. 
Next, to focus on the role of PDGF-B in cardiac allograft ischemia-reperfusion injury, 
coronary arteries of the donor hearts were perfused of adenoviruses encoding ?-Galactosidase 
marker gene (LacZ) or recombinant human full-length PDGF-BB and the allografts were 
subjected to 2 hours cold ischemia before transplanted to MHC-mismatched recipients. At 10 
days, ELISA analysis of serum syndecan-1, an indicator of endothelial glycocalyx shedding, 
was used to evaluate endothelial injury of cardiac allografts. Serum syndecan-1 levels were 
20-fold higher in Ad.LacZ -perfused allografts when compared to serum levels of native rats 
(Figure 15A). In Ad.hPDGF-BB -perfused allografts serum syndecan-1 levels were 
significantly lower when compared to Ad.LacZ controls (Figure 15A). Quantitative real time 
RT-PCR revealed that hPDGF-BB gene transfer induced mRNA expression of BMP-7, an 
inhibitor of the endothelial-mesenchymal transition (Figure 15B) (Zeisberg et al. 2007), and 
anti-apoptotic Bcl-2 (Figure 15B). Next, we analyzed cardiac allograft capillary and artery 
densities. In control cardiac allografts RECA1+ myocardial capillary density was decreased 
when compared to native DA rat hearts. Gene transfer of hPDGF-BB preserved cardiac 
allograft RECA1+ endothelial phenotype (Figure 15C). The ?-SMA+ vessel densities were not 
affected at 10 day by Ad.hPDGF-BB gene transfer (Figure 15D). PDGF receptor tyrosine 
kinase inhibitor imatinib mesylate increased endothelial glycocalyx shedding and 
cardiomyocyte injury evidenced by elevated serum syndecan-1 and cTnT (Figures 15E and 
15F). Finally, in major MHC-mismatched mouse allograft donors treated with specific 
PDGFR-? and -??mAbs, inhibition of PDGFR-?, but not -? induced myocardial damage 6
hours after reperfusion, when compared to IgG controls (Figure 15 G). 
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Figure 15. First, cardiac allografts were perfused with adenoviral (Ad.) vectors containing either LacZ control 
gene or human PDGF-BB ligand. Cyclosporine A background immunosuppression was administered to the 
cardiac allograft recipients as 2.0 mg/kg for 7 days and 1.0 mg/kg daily thereafter. (A) Serum syndecan-1 levels, 
an indicator of endothelial injury, (B) mRNA expression levels of central genes involved in microvascular 
homeostasis, mesenchymal transition and survival and myocardial densities of (C) RECA-1+ capillaries and (D) 
?-SMA+ arteries were determined 10 days after transplantation. The inhibition of PDGF receptor activity in rat 
cardiac allograft ischemia-reperfusion on (E) endothelial and (F) cardiomyocyte injury was evaluated at 6 hours. 
(G) The effect of specific PDGFR-? and -? inhibition on mouse cardiac allograft myocardial injury after 
ischemia-reperfusion at 6 hours. Arrows indicate TUNEL+ apoptotic nuclei. Scale bars=50 ?m. Unpublished 
data.
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DISCUSSION
Microvasculoprotective effects of simvastatin
During static cold preservation, a transplant is predisposed to ischemia and loss of nutrients. 
Moreover, withdrawal from blood flow excludes a transplant from physiological pulsatile 
vascular wall shear stress. Both ischemia and metabolic changes together with loss of shear 
stress disturb vascular and parenchymal homeostasis (Figures 16 and 17). Microvascular 
dysfunction plays a critical role in Tx-IRI, allograft dysfunction and the development of 
untreatable allograft vasculopathy (Hollenberg et al. 2001; Marti et al. 2001; Tona et al. 
2006; Kubrich et al. 2008). As the potential cellular effects of donor simvastatin treatment are 
carried along with the transplant, the possible primary targets are transplant tissue cells and 
passenger leukocytes. The exact role of different cell types in mediating the protective effects 
of statins in Tx-IRI in kidney and cardiac allografts is difficult to determine in vivo but 
several of our findings point out that pleiotropic cholesterol-independent microvascular 
protection has a pivotal role. First, the cholesterol levels of rats were low with a low-
cholesterol diet, and the levels were not affected by simvastatin treatment. Second,
immunohistochemical and immunofluorescence double-stainings revealed that the 
simvastatin target molecule HMG-CoA reductase was mainly expressed in the 
microvasculature of the rat heart and kidney. Third, donor simvastatin treatment upregulated 
the mRNA expression of multiple vasculoprotective genes during heart and kidney 
preservation and maintained microvascular integrity. Fourth, donor simvastatin treatment 
prevented the microvascular permeability and perfusion disturbances very early after 
reperfusion. Fifth, simvastatin inhibited the release of vasoactive peptides ET-1 and Ang-2
into the media of human blood endothelial cells in vitro. Sixth, donor simvastatin treatment 
together either with geranylgeranyl pyrophosphate or with L-NAME demonstrated that the 
RhoA/ROCK and NO pathways are directly involved in the vasculoprotective effects of 
simvastatin in our models. 
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Figure 16. Multiple signaling pathways regulating vascular homeostasis, inflammation, fibrosis and survival are 
affected by ischemia and loss of shear stress during allograft cold preservation. Downward arrowhead =
downregulation of pathway activity by allograft cold preservation. Underline indicates factors affected by donor 
simvastatin treatment.
Anti-inflammatory effects of simvastatin and methylprednisolone are divergent
Until the initiation of immunosuppressive treatment targeting to the inhibition of T cell 
activation by calcineurin inhibitors, acute cellular rejections limited the use of cadaveric 
organ transplantations as an established treatment option for end-stage heart and kidney 
disease. However, malignancies, infections and cardiovascular side-effects of 
immunosuppressive medication are among major causes for mortality after transplantation. 
Statins mediate anti-inflammatory effects through HMG-CoA reductase and integrin 
leukocyte function-associated antigen (LFA)-1 -dependent pathways (Weitz-Schmidt et al. 
2001). As donor simvastatin treatment may affect allograft passenger leukocytes, we 
investigated the effect of simvastatin on the phenotype and T cell stimulation properties of 
macrophages. Simvastatin treatment downregulated both TNF-? and iNOS (M1 macrophage 
factors) and Arg-1 (M2 macrophage factor), and did not alter T cell stimulation. These results 
suggest that donor simvastatin treatment may not alter the M1/M2 polarization of passenger 
leukocytes or their antigen presentation properties. MHC II mRNA expression of allografts, 
on the other hand, was downregulated already 6 hours after reperfusion, indicating decreased 
immunogenic potential. Overall, it seems that donor simvastatin treatment inhibited 
microvascular dysfunction, allograft damage, and activation of innate immunity and 
maturation of APC. We think this in turn decreases the priming of alloreactive T cells. 
Combined donor simvastatin and methylprednisolone treatment, however, resulted in 
microvasculoprotective and immunomodulatory effects (Figure 16). Methylprednisolone 
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reduced chemotactic and pro-inflammatory NF-?B, IL-8, MCP-1 and MIP-1? mRNA 
expression and combined with simvastatin, the treatment was more effective in reducing 
innate immunity cells neutrophil infiltration, myocardial injury and acute rejection than either 
treatment alone. 
Figure 17. Ischemia-reperfusion injury (IRI) induces infiltration of inflammatory cell by microvascular 
cytoskeletal reorganization and expression of pro-inflammatory and innate immune ligands. Combined donor 
simvastatin and methylprednisolone treatment resulted in dual vasculoprotective and immunomodulatory 
effects. Simvastatin (italic) reduced the RhoA and Rac1 mRNA expression of RhoGTPases and decreased 
microvascular RhoA signaling, while methylprednisolone (bold) decreased myocardial danger ligand hyaluronic 
acid (HA) accumulation and expression of chemotactic cytokines IL-8, MCP-1, MIP-1???The donor 
combination treatment efficiently reduced the number of allograft-infiltrating macrophages and neutrophils. 
Figure drawn by Simo Syrjälä. 
Antifibroproliferative effects of simvastatin
Transforming growth factor (TGF)-?1 secretion is induced by many cell types during Tx-
ischemia-reperfusion and rejection responses in cardiac and kidney allografts (Waltenberger 
et al. 1993; Zhao et al. 1994; Lario et al. 2003). TGF-?1 has been postulated to exert a broad 
spectrum of effects. TGF-?1 may protect the myocardium from IRI and mediate 
immunosuppressive effects (Dandapat et al. 2008). On the other hand, TGF-?1 may promote 
apoptosis, permeability and epithelial-to-mesenchymal (EMT) and endothelial-to-
mesenchymal transition (EndMT) in hearts and kidneys (Behzadian et al. 2001; Bhowmick et 
al. 2001; Zeisberg et al. 2007). Donor simvastatin treatment decreased fibroproliferative 
activity and development of fibrosis in cardiac and kidney allografts. This was likely 
mediated both through direct and indirect effects. Direct antifibrotic effects may include 
inhibition of RhoA, which is necessary for TGF-?1 induced mesenchymal transition 
(Bhowmick et al. 2001); (Patel et al. 2006) (Figure 18). We found that simvastatin in a dose-
dependent manner inhibited TGF-?1 induced loss of tight junctions and fibrotic phenotype in 
human cardiac microvascular endothelial cell cultures. Thus, we hypothesized that targeting 
endothelial stability may have antifibroproliferative potential. Also, donor simvastatin 
treatment reduced the expression of many pro-fibrotic genes, presumably mediated partly via 
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reduced endothelial activity and allograft infiltration of inflammatory cells, sources for bFGF, 
ET-1, PDGF-A and TGF-?1.
Figure 18. Endothelial–to-mesenchymal transition (EndMT) is a physiological process during heart and kidney 
development, but is not observed in quiescent adult vasculature. In transplantation, reorganization of the actin 
cytoskeleton and extracellular matrix by hypoxia-induced RhoA and inflammatory cytokine TGF-?1 play a 
pivotal role in endothelial cell plasticity to undergo EndMT. EndMT has a pathological role in cardiac and 
kidney allograft fibrosis. Donor simvastatin treatment inhibited both RhoA and TGF-?1 mRNA expression and
down-stream signaling, and preserved myocardial capillary intensity, a possible antifibroproliferative 
mechanism through EndMT inhibition. Figure modified from Potenta S et al., British Journal of Cancer, 2008. 
The role of PDGF ligands in cardiac allografts
In cardiac transplantation, angiogenic growth factors are triggered rapidly after a mechanical 
vascular injury or after a drop in oxygen level. If we postulate angiogenic growth factors to 
be protective during cardiac transplant I/R -injury, as was shown with myocardial ischemia-
reperfusion and infarction models (Hsieh et al. 2006a; Hsieh et al. 2006b), ensuring 
endothelial viability or even pharmacological supplementation of endothelial derived 
angiogenic growth factors could facilitate protection from at least vascular SMC and 
cardiomyocyte death. Therefore, it is fascinating to speculate that angiogenic growth factors 
may have a bidirectional role in heart transplantation. On short term, they may mediate 
physiological protection of the heart against transplant I/R -injury, on the other hand; during 
prolonged upregulation they may direct pathological consequences, such as intimal formation 
via vSMC “neoplasia”. Here we showed that persistent overexpression of PDGF ligands -A, 
-C and -D induced TGF-?? mRNA expression and chronic rejection in rat cardiac allografts. 
Yet, the role of PDGF ligands in ischemia-reperfusion of cardiac allografts remains unsolved.  
Study limitations
Our cardiac and kidney transplantation models in rats and mice were performed exclusively 
between major MHC-mismatched recipients. Further, we used clinically relevant organ 
preservation and warm ischemia times, donor treatment was designed to fit the clinical use 
and background immunosuppression took care. However, our experimental models did not 
and cannot take into account all the variables involved in the clinical situation. The principal 
concern regarding our models is the lack of donor brain death. As donor treatment with 
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another lipophilic HMG-CoA reductase inhibitor, atorvastatin, for 2 days failed to protect 
kidney allografts from rejection in an extreme non-immunosuppression brain death model 
(Hoeger et al. 2012), it is justified to question whether the microvasculoprotective effects of 
donor simvastatin treatment or adenoviral PDGF-BB transgene expression withstand in even 
more severe models. 
Clinical implications
Based on our studies, pharmacokinetics of donor simvastatin treatment fits to the narrow 
time-window to treat a cadaveric organ donor from the declaration of brain death to organ 
procurement. In contrast to recipient statin treatment, donor statin treatment targets the 
transplanted organ and the very proximal events that may lead to early allograft injury and 
predispose the organ to the development of delayed graft function and acute and chronic graft 
failure. Therefore, the vasculoprotective effects of statins may not be restricted to specific 
organs – important information when considering donor simvastatin treatment and multi-
organ donation. We have therefore initiated a randomized clinical trial to investigate the 
effect of donor simvastatin treatment as an adjunct therapy on short- and long-term results of 
cardiac, lung, and kidney allografts.
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CONCLUSIONS
Overall, we believe that the effect of donor simvastatin treatment is primarily due to 
cytoskeletal stabilization of microvascular endothelial cells and pericytes, which leads to 
decreased permeability and perfusion defects, infiltration of innate immune cells and IRI in 
the allografts. As a consequence of less tissue injury, the damage associated molecular 
patterns do not activate Toll-like receptors on passenger leukocytes and graft infiltrating 
macrophages, which leads to decreased antigen presentation on alloreactive T cells in 
secondary lymphoid organs and finally decreased infiltration of alloreactive T cells into the 
allografts. In multi-organ donor situation, simvastatin may offer a feasible microvascular-
targeted adjunct therapy for organ protection by preventing activation of immune responses 
after Tx-IRI.
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YHTEENVETO (FINNISH SUMMARY)
Mikrovaskulaari dysfunktio sydän- ja munuaissiirteen iskemia-reperfuusiovauriossa
Sydän- ja munuaissiirteiden lyhyt- ja pitkäaikainen eloonjäämisennuste on viime 
vuosikymmeninä parantunut huomattavasti ja sen vuoksi potilaita listataan sydän- ja 
munuaissiirtoihin yhä enenevissä määrin. Aikaisemmmin elinluovuttajat olivat nuoria ja 
terveitä lukuunottamattta aivokuolemaan johtanutta tapahtumaa. Koska elinluovuttajien puute 
rajoittaa tehtävien elinsiirtojen määrää, elinluovuttajiksi joudutaan hyväksymään yhä 
iäkkäämpia ja monisairaita potilaista, joita aivokuolema on kohdannut. Kuitenkin, kaikista 
elinluovuttajista vain 20–40% päätyy sydänluovuttajiksi. Jotta sydänluovuttajien osuutta 
saataisiin kasvatettua, elinluovuttajien hoitoa tulisi kehittää.
Sydänsiirrettä kuormittavat verenkiertosairauden ohella siirteeseen vaikuttavat ei-
immunologiset (mm. iskemia-reperfuusiovaurio) ja immunologiset (mm. alloimmuunireaktio) 
vasteet sekä immunosuppressiivisen lääkityksen sivuvaikutukset. Nämä edesauttavat 
kroonisen hyljintäreaktion kehittymistä. Pitkäaikaishyljinnän vallitsevina piirteinä ovat 
sydänsiirteen valtimopuuston kiihtynyt ja diffuusi ahtautuminen, etenevä parenkyymin
fibrotisoituminen sekä voimakas tulehdussoluinfiltraatio ja kudosnekroosi. Kylmäsäilytysajan 
pituus on merkittävimpiä ennustetekijöitä siirteen toimivuudelle.
Viime vuosina on selvinnyt, että statiinihoidon sydän- ja verenkiertosairauksiin sairastavuutta 
ja kuolleisuutta vähentävä teho on selvästi sen kolesterolivälitteisiä vaikutuksia laajempi. 
Statiinilääkitys liitetään muun immunosuppresiivisen hoidon oheen elinsiirtopotilaille, mikäli 
heillä ei tätä ennestään ole käytössä. Statiinin on todettu parantavan sydän- ja 
munuaissiirteiden pitkäaikaisennustetta sekä kolesterolitasoa alentavien että suorien anti-
inflammatoristen vaikutusten kautta. Elinsiirteen luovuttajat sitä vastoin ovat usein 
tapaturmaisesti aivokuolleita, eikä heillä yleensä ole ollut statiinilääkitystä. Tavoitteenamme 
oli selvittää elinluovuttajan simvastatiinihoidon vaikutusta sydän- ja munuaissiirteiden 
kylmä- ja lämminsäilytykseen, iskemia-reperfuusiovaurioon ja hyljintäreaktion 
käynnistymiseen.
Koe-eläinmallissamme käytimme maksimaalisesti MHC-kudostyypiltään toisistaan 
poikkeavia sisäsiittoisia DA ja WF rottakantoja. Altistimme sydänsiirteet 4 tunnin kylmä- ja 
1 tunnin lämminsäilytykselle ja munuaissiirteet 16 tunnin kylmä- ja 1 tunnin 
lämminsäilytykselle. Tutkimuksessa osoitettiin, että elinsiirteen luovuttajan 
simvastatiinihoidon hyöty perustui pääosin lääkkeen verisuonistoa suojaaviin vaikutuksiin. 
Kliinisesti soveltuva kerta-annos simvastatiinia annettuna 2 tuntia ennen sydän- ja 
munuaissiirteen irroitusta esti verisuonien endoteelissa ja perisyyteissä stressisäikeiden 
muodostusta, endoteeliväliliitosten aukeamista ja verisuonien läpäisevyyden kasvua sekä 
verisuonien tukisolujen (perisyyttien) supistuvuutta ja kudosperfuusiohäiriöitä. Havaitsimme,
että elinluovuttajien simvastatiinilla lääkityissä sydän- ja munuaissiirteissä akuutti 
sydänlihas- ja tubulusvaurio sekä fibroosia ja tulehdusta välittävien geenien tuotanto oli 
merkittävästi vähäisempää, mikä heijastui vähentyneeseen sydänsiirteen valtimopuuston 
ahtautumiseen ja parantuneeseen pitkänaikavälin ennusteeseen. Elinluovuttajan simvastatiini-
esilääkityksen yhdistäminen metyyliprednisoloni-esilääkitykseen tarjosi tehokkaan sekä 
verisuonia suojaavan että tulehdusta rauhoittavan vaikutuksen, mikä heijastui parantuneeseen 
sydänsiirteiden ennusteeseen akuutin hyljintäreaktion aikana.
Koeasetelma vastaa kliinistä sairaalatilannetta, jossa aivokuoleman jälkeen teho-osaston 
anestesialääkärille tarjoutuu muutaman tunnin aikaikkuna hoitaa elinluovuttajaa ennen elinten 
irrotusvaihetta. Perustutkimustulosten pohjalta olemme käynnistäneet HUS:n eettisen 
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toimikunnan luvalla kliinisen randomisoidun tutkimuksen, jossa elinsiirteiden luovuttajia 
esilääkitään vastaavalla koeasetelmalla. Luovuttajan esilääkitys simvastatiinilla tarjoaa
lupaavan hoitomahdollisuuden elinsiirtopotilailla ilman elinsiirteen vastaanottajaan 
kohdistuvia sivuvaikutuksia.
 
 68 
SAMMANFATTNING (SWEDISH SUMMARY)
Mikrovaskulär dysfunktion i hjärt- och njurtransplantat med ischemia-reperfusion 
skador 
Långtidsprognosen för hjärttransplantationer är rätt dålig trots flera framsteg som tagits under 
de senaste åren. Hjärttransplantaten belastas såväl av blodomloppssjukdomar, immunförsvar-
relaterade (bl.a alloimmun-reaktioner) och -orelaterade (bl.a sk. ischemia-reperfusion skador) 
reaktioner såsom biverkningar förorsakade av immunosuppressiv medicinering. Dessa 
faktorer befrämjar utveklingen av en kronisk lågtidsrejektionsreaktion som karakterisesras av 
artärgrenarnas accelererade förträngning i transplantatet. Kylförvarning är en av de viktigaste 
enskilda prognosfaktorena för funktionen av transplantatet.
Under de senaste åren har det påvisats att statiner förbättrar prognosen för hjärt- och 
njurtranslantationer, både via sin nedsättande effekt på kolesterolmetabolin och via sin anti-
inflammatoriska påverkan. Statinmedicinering har tillämpats vid behandlingen av 
transplantationspatienter vid sidan om den immunosuppressiva medicineringen. 
Organdonorerna å andra sidan, är i allmänhet friska individer som blivit hjärndöda på grund 
av olycksfall, och därmed saknar ofta föregående statinmedicinering. Vårt mål var att utreda 
simvastatin-behandlingens inverkan på hjärt- och njurtransplantatens kall- och 
varmförvarning, iskemia-reperfusion samt initiering av rejektionsreaktionen.
I vår försökskonstellation användes råttan som modell för hjärt- och njurtransplantationer. 
Hjärttransplantat utsattes för 4 timmars kall- och 1 timme varmförvaring medan 
njurtransplantat utsattes för 16 och 1 timme, respektive förvarningstyp. Resultaten påvisar att 
nyttan med transplantatdonorens statin förbehandling grundar sig främst på statinets 
skyddande inverkan på blodådrorna. Den kliniskt anpassade engångsdosen för simvastatin, 2h 
före lösgörning av hjärt- och njur transplantaten, förhindrade bildningen av stressfibrer i 
blodådrornas endotelceller, öppningen av endotelfogarna, ökning av blodådrornas 
permeabilitet samt perisytkontraktilitet och förstörningar i vävnadsperfusion. Våra resultat 
påvisar att simvastatin förbehandling av hjärt- och njurtransplantat, leder till en  nedreglerad 
expression av gener som styr bildningen av fibros och inflammatonsreaktion, nedsatt 
förträngning av artärgrenar i hjärttransplaten och en förbättrad prognos för 
långtidsrejektioner. Då transplantatdonorens simvastatinförbehandling kombineras med en 
metylprednisolonförbehandling, uppnås en effekt som både skyddar blodådror och lindrar 
inflammationsreaktioner, och därmed förbättrar hjärttransplantatets prognos under en akut 
rejektion.
Vår försökskonstellation motsvarar verkligheten i och med att i fall av patientens hjärndöd, 
kan förmedicinering tillämpas på donoren före lösgöring av transplantatet. Resultaten som 
uppnåtts genom denna basforskningen har tillämpats vid HUS till att starta ett kliniskt 
randomiserat försök, där transplantatdonorer förmedicineras i enlighet med vår 
forskningskonstellation. Simvastatin förmedicinering utgör ett lovande vårdalternativ, utan 
belastande biverkningar på transplantatacceptorn.
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